Sexual Dimorphism in Aortic Function of UC Davis Type 2 Diabetes Mellitus Rat Model: Estrogen Specific Responses by Akther, Farjana
Masthead Logo
University of the Pacific
Scholarly Commons
University of the Pacific Theses and Dissertations Graduate School
2019
Sexual Dimorphism in Aortic Function of UC
Davis Type 2 Diabetes Mellitus Rat Model:
Estrogen Specific Responses
Farjana Akther
University of the Pacific, abr_jigs@yahoo.com
Follow this and additional works at: https://scholarlycommons.pacific.edu/uop_etds
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Dissertation is brought to you for free and open access by the Graduate School at Scholarly Commons. It has been accepted for inclusion in
University of the Pacific Theses and Dissertations by an authorized administrator of Scholarly Commons. For more information, please contact
mgibney@pacific.edu.
Recommended Citation
Akther, Farjana. (2019). Sexual Dimorphism in Aortic Function of UC Davis Type 2 Diabetes Mellitus Rat Model: Estrogen Specific
Responses. University of the Pacific, Dissertation. https://scholarlycommons.pacific.edu/uop_etds/3600
1 
 
SEXUAL DIMORPHISM IN AORTIC FUNCTION OF UC DAVIS TYPE 2 
DIABETES MELLITUS RAT MODEL: ESTROGEN SPECIFIC RESPONSES 
 
 
by 
 
 
Farjana Akther 
 
 
 
 
 
A Dissertation Submitted to the 
Graduate School 
In Partial Fulfillment of the 
Requirements for the Degree of 
DOCTOR OF PHILOSOPHY 
 
 
Thomas J. Long School of Pharmacy and Health Sciences 
Pharmaceutical and Chemical Sciences 
 
 
 
 
 
 
 
 
 
 
 
 
University of the Pacific 
Stockton, California 
 
2019 
 
 
2 
 
SEXUAL DIMORPHISM IN AORTIC FUNCTION OF UC DAVIS TYPE 2 
DIABETES MELLITUS RAT MODEL: ESTROGEN SPECIFIC RESPONSES 
 
 
 
 
 
 
by 
 
Farjana Akther 
 
 
 
 
 
 
 
 
 
 
APPROVED BY: 
Dissertation Advisor:  Dr. Roshanak Rahimian, Ph.D. 
Committee Member:  Timothy Smith, Ph.D. 
Committee Member:  David Thomas, Ph.D. 
Committee Member:  James A. Uchizono, Pharm. D., Ph.D. 
Committee Member:  Aditya Goel, Ph.D. 
Dean of Graduate School:  Thomas Naehr, Ph.D. 
 
 
 
 
 
 
 
3 
 
SEXUAL DIMORPHISM IN AORTIC FUNCTION OF UC DAVIS TYPE 2 
DIABETES MELLITUS RAT MODEL: ESTROGEN SPECIFIC RESPONSES 
 
 
 
Copyright 2019 
 
By 
 
Farjana Akther 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
DEDICATION 
 
 
This dissertation is dedicated to my father Md. Nurul Alam, mother Bulbul Akther, loving 
husband Md. Zahir Uddin and our son Azan Zahir. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
ACKNOWLEDEGEMENTS 
 
 
I would like to express my sincere gratefulness to my advisor Dr. Roshanak Rahimian for giving 
me the opportunity to work with her.  I thank Dr. Rahimian, for her continuous support, 
guidance, and suggestions throughout the course of Ph.D.  It has been an honor to be one of her 
Ph.D. students.  I appreciate all her contributions of time, ideas, and funding to make my Ph.D. 
experience very smooth and productive.  Her enthusiasm towards vascular research and women 
health has inspired me.  She has instilled in me with a drive for research in women's health and 
has provided us with an excellent example as a successful woman scientist.  Also, I have been 
extremely lucky to have a supervisor who cared so much not only about my work and career, but 
also about my family.  I sincerely appreciate her efforts to bring collaborations and introducing 
us to Dr. Marta Alegret and Dr. Juan Carlos.  I would like to thank Dr. James Uchizono, Timothy 
J smith, Dr. David Thomas and Dr. Aditya Goel for their suggestions and being on my 
committee.  I would like to thank Dr. Chan for letting me use the Licor Odessey in his 
laboratory.  I thank Ms. Bonnie O'Hearn Ms. Kathy Kassab and Lynda Davis for all their help 
during my course of study.  I am very grateful to my labmates- Sharon, Sonali, Gemma and 
Razan forr making my PhD life fun-filled and exciting, especially I would like to thank Razan 
for being a wonderful team member during my PhD work.  I appreciate Dr. Swetha, Michael Ng 
and Dr. Jiyeun Cao for teaching me western blot technique.  I greatly appreciate our IT 
department staff- Tim and Minh, for their invaluable help during my course of PhD. I thank my 
sister Farah for her support, motivation and being there for me.  I would like to appreciate Razan, 
Rownak, Tuhin, Arindom, Rita and Toufiq for their support and friendship. 
Finally, I would thank my parents, my mother in law, my husband and our son for their help and 
support that made all this possible.  They are the most important persons in my life.  I would 
6 
 
especially like to thank my husband for his unconditional love and support.  Lastly and most 
importantly, I wouldn't have been where I am today without the blessing and support of my dad, 
Md. Nurul Alam whom I lost in 2016.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
 
Sexual Dimorphism in Aortic Function of UC Davis Type 2 Diabetes Mellitus Rat 
Model: Estrogen Specific Responses 
 
 
Abstract 
 
 
By Farjana Akther 
 
University of the Pacific 
2019 
 
 
Little is known about the interaction between diabetes and sex in vasculature.  This study 
was designed to investigate the effects of estrogen as well as type 2 diabetes (T2D) on aortic 
function in rats with respect to sex.  To test the effects of T2D and sex, UC Davis Type 2 
Diabetes Mellitus (UCD-T2DM) rat model was used.  To study the effects of estrogen, 
ovariectomized Sprague- Dawley female rats and UCD-T2DM rats at pre-diabetic stage were 
used and the rats were implanted subcutaneously either with placebo or 17 β-estradiol pellets (60 
days release, 1.5mg/pellets).  The plasma analytes for metabolic parameters and aortic responses 
to vasodilator and vasoconstrictor agents were determined.  The expression of molecules 
associated with vascular response (e.g. endothelial nitric oxide (NO) synthase (eNOS), Nox1, 
Nox4, intermediate conductance calcium-dependent potassium channels (IKCa) and small 
conductance calcium-dependent potassium channels (SKCa)) were also evaluated in aortic tissue.   
The main objectives of the study were whether 1) sex differences exist in the 
development of abnormal vascular responses of UCD-T2DM rats, 2) there were changes in the 
relative contributions of endothelium-derived relaxing factors (EDRFs) in modulating vascular 
reactivity of aorta, and 3) estrogen replacement improves the aortic function of ovariectomized 
UCD-T2DM rats at pre-diabetic stage. 
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In the study of examining the effect of sex and T2D, diabetes significantly impaired 
relaxation responses to ACh and SNP in aortic rings from female UCD-T2DM rats, however, 
potentiated the relaxation in males.  The responsiveness to PE was significantly enhanced in both 
diabetic groups regardless of sex.  Accordingly, the basal nitric oxide (NO), as indicated by the 
potentiation of the response to PE after L-NAME, was reduced in aorta of both diabetic groups.  
Blocking of COX, sGC and NOS completely abolished the relaxation response in female diabetic 
group whereas male diabetic animals showed a significant remaining relaxation response to 
ACh.  Further incubation of aortic rings of male animals with TEA or TRAM 34 blunted the 
relaxation responses to ACh in both control and diabetic groups.  However, the inhibitory effects 
of TEA or TRAM 34 on the ACh-induced relaxation in male UCD-T2DM group was greater 
than their respective controls.  By contrast, ACh responses were not affected following 
incubation with Apamin in either group of male rats.  Moreover, protein expression of IKca were 
significantly higher in male diabetic group compared with the respective controls. 
In the estrogen replacement study, treatment with E2 markedly enhanced the ACh 
responses of aortic rings in both control and pre-diabetic groups compared to respective placebo 
treated group.  Moreover, effect of E2 in improving the ACh induced relaxation response was 
significantly higher in control group compared with pre-diabetic animals. The responsiveness to 
PE were significantly reduced in both E2 treated groups.  Basal NO level was significantly higher 
in both E2 replaced groups but in control group the level was significantly higher than the pre-
diabetic rats.  Also, protein expression level of Nox1 were decreased in E2 treated control and 
pre-diabetic group but eNOS were enhanced only in E2 treated control groups.    
In conclusion, this study suggests that the effects of type 2 diabetes on aortic ring are sex 
specific and we showed a differential contribution of EDRFs in male UCD-T2DM rats.  
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Furthermore, our data suggests that elevated eNOS and decreased Nox1protein level may 
contribute to the higher impact of estrogen in ovariectomized control groups compared to the 
pre-diabetic rats. 
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Chapter 1: Introduction 
Cardiovascular diseases (CVD) are the major causes of morbidity and mortality in 
patients with diabetes.  In healthy premenopausal women, the risk for CVD is lower compared to 
age-matched men (1-3).  However, women after menopause experience higher incidence of 
CVD.  This presumably related to the reduced level of estrogen (4-6).  Multiple studies have 
shown that premenopausal women with diabetes not only lose the sex-based cardiovascular 
protection but also experience a higher relative risk of CVD compared to diabetic men (7-9).  
According to the “Female and CVD- 2019 Statistical Fact Sheet”, CVD accounts for the highest 
percent (49%) of total death among female in United States, claiming over 412,244 deaths in 
2016 (10). 
1.1 Cardiovascular Diseases 
CVDs are considered as a class of diseases of  the heart and blood vessels which includes 
heart failure, coronary artery diseases, stroke, cardiomyopathy, peripheral artery disease, venous 
thrombosis, thromboembolic disease etc. (11).  CVD are the number 1 cause of death globally 
(12).  In 2016, approximated 17.9 million people died from CVD and 85% of these deaths 
occurred due to heart attack and stroke (12).  Stroke and heart attacks mainly results from 
blockage of blood vessels that prevents the blood flow into the brain or heart.  This blockage 
occurs mainly due to fatty deposits on the inner walls of the blood vessels (13).  The common 
risk factors of developing CVDs include diabetes, hypertension, unhealthy diet, obesity, 
hyperlipidemia, tobacco use and physical inactivity.  People with CVD or who are at high 
cardiovascular risk, has one or combination of risk factors. 
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1.2 Diabetes 
In United States 30.3 million people have diabetes mellitus which is around 10% of the 
total U.S. population.  84.1 million U.S. adults have prediabetes.  It is estimated that as many as 
1 in 3 American adults will have diabetes in 2050 (data from American Diabetes Association and 
CDC).  
According to WHO, diabetes is a chronic disease that occurs either when the pancreas 
does not produce enough insulin or when the body cannot effectively make use of the insulin 
produced (13).  In patients with diabetes, high blood glucose can lead to several vascular 
diseases including micro-and macro-vascular consequences, like atherosclerosis, retinopathy and 
nephropathy. 
1.2.1 Type 1 diabetes mellitus. Type 1 diabetes mellitus (T1DM) (previously known as 
insulin-dependent diabetes mellitus (IDDM)) is a form of diabetes mellitus in which pancreatic 
beta cells fail to produce enough insulin, leading to insulin deficiency.  This type can be further 
classified as immune-mediated or idiopathic because T- cell mediated autoimmune attack 
destroy beta cells in the pancreas (14).  In North America and Europe, T1DM accounts for 
around 5% of diabetes mellitus cases and there is no known preventive measure against it. 
1.2.2 Type 2 diabetes mellitus. Type 2 diabetes mellitus (T2DM) is a type of metabolic 
disorder which is characterized by high blood glucose along with insulin resistance and relative 
insulin deficiency.  Insulin resistance occurs primarily within the liver, muscles and adipose 
tissue.  After developing insulin resistance cells lose the ability to respond adequately to normal 
levels of insulin.  Although the specific defects are not known, insulin receptors are thought to be 
involve for the defective responsiveness of insulin to body tissues.  T2DM accounts for 90% of 
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cases of diabetes.  Several factors besides genetics are involved in the developments of T2DM 
such as lifestyle, age, obesity, diet, female sex hormones etc.  Therefore, T2DM can be managed 
partly by lifestyle modification i.e. healthy diet and exercise.  Diabetes ultimately leads to 
macrovascular and microvascular diseases due to the damage in large and small arteries 
respectively. 
1.2.3 Gestational diabetes. Gestational diabetes is a form of diabetes which develops in 
some women during pregnancy.  Majority of diabetes diagnosed during pregnancy is type 2 
diabetes.  Generally, after giving birth this type of diabetes does not exist.  However, the person 
with gestational diabetes has a higher chance of developing T2DM in the later stage of life. 
1.3 Diabetes and Cardiovascular Diseases 
One of the major risk factors for CVD is diabetes.  Both type 1 and type 2 diabetes are 
closely related to CVD.  Diabetes causes cardiovascular damage in several ways and each may 
worsen or accelerate the effect of others.  Thus, the heart and blood vessels are subjected to 
multiple attacks as diabetes progresses.  It is more likely to develop CVD in individuals with 
diabetes than those without diabetes.  Therefore, patients with diabetes are at high risk of 
morbidity and mortality due to the development of cardiovascular complications. 
1.4 Endothelial Functioning 
Endothelium is an inert anatomical barrier between blood and the vessel wall. It forms 
the inner lining of all vasculature.  Under physiological and pathological conditions, endothelial 
cells act by releasing a variety of relaxing and contracting factors which can regulate the basal 
vascular tone by responding to neurohumoral mediators and mechanical forces (15). In the 
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pathogenesis of diabetic vascular disease, endothelial dysfunction plays a major role.  
Endothelial dysfunction refers to an impairment of the ability of endothelium to properly 
maintain the vascular homeostasis.   
Endothelial cells regulate the tone of underlying vascular smooth muscle cells (VSMC) 
by producing several mediators of vasodilation.  The endothelium-derived relaxing factors 
(EDRF) include nitric oxide (NO), prostacyclin, and endothelium-derived hyperpolarizing 
factors (EDHF).  In addition, endothelial cells also release several vasoconstrictor prostanoids 
(endothelium-derived contracting factors, EDCF).  Endothelial dysfunction occurs when the 
release of EDRFs decreased and if the propensity of EDCF production is increased.  This is the 
first step in the chain of events which ultimately leads to atherosclerosis and coronary disease 
(16).  Endothelium-dependent vasodilation (EDV) is used as a reproducible parameter to probe 
endothelial function in different pathophysiological conditions (17) . It has been observed that 
EDV is impaired in various vascular beds of different diabetic animal models and in humans 
with type 1 and type 2 diabetes.  The initiating factor in the development of diabetic vascular 
disease is the loss of modulatory role of endothelium.  Although, the cellular basis of endothelial 
dysfunction in CVD with diabetes is widely studied but the interaction of sex with these 
conditions is not fully understood and demands detailed investigation.  Impairment of EDV may 
occur through several mechanisms: decreased bioavailability of EDRFs, decreased 
responsiveness of the smooth muscle to EDRF and enhanced generation of EDCFs. 
1.4.1 Nitric Oxide (NO). NO is produced through oxidation of L-arginine to L-citrulline 
by nitric oxide synthase (NOS).  Different isoforms of NOS differ in structure and in function 
(18).  There are three distinct isoforms of NOS : nNOS (neuronal NOS; type I), iNOS (inducible 
NOS, type II) and eNOS (endothelial NOS, type III).  eNOS and nNOS are referred to as Ca2+-
25 
 
dependent enzymes and these enzymes are expressed constitutively.  iNOS is Ca2+- independent 
and induced by immunological stimuli such as cytokines, bacterial lipopolysaccharide and other 
agents.    nNOS plays a role in cell communication and produces NO in skeletal muscle and 
nervous tissue.  NO generated by eNOS plays a key role in the vascular tone regulation involving 
vasodilation, inhibition of leukocyte adhesion and vascular inflammation, inhibition of platelet 
aggregation and adhesion, regulation of vascular smooth muscle proliferation, angiogenesis 
stimulation, and endothelial progenitor cells activation (19).  
eNOS is activated by agonists such as ACh which binds to G-protein-coupled receptors 
on the endothelial cell membrane, therefore increases the concentrations of intracellular Ca2+  
and the increased Ca2+ binds to the calmodulin (20).  NO mediates the formation of cyclic 
guanosine monophosphate (cGMP) by activating soluble guanylate cyclase and facilitates the 
vasodilation by diffusing into VSMCs (Figure 1). NO is metabolized rapidly to nitrite and then to 
nitrate before being excreted in the urine (21). The half-life of NO is less than 4s.   
eNOS can also be activated by shear stress and the activation depends on ATP-gated Ca2+ 
channels that activates phosphatidylinositol 3-kinase (PI3K), leading to activation of protein 
kinase B (Akt), which directly phosphorylates eNOS on Ser1177, causing activation of eNOS 
(20, 22).  A reduced activity and/or expression of eNOS could be responsible for a decrease in 
NO production.  Notably, decreased NO production and/or increased NO elimination are closely 
associated with endothelial dysfunction.   
In addition, accelerated degradation of NO by reactive oxygen species (ROS) is probably 
the major mechanism impairing NO bioavailability in diabetes.  Uncoupling of eNOS due to 
oxidative stress can lead to the formation of superoxide (O2•-) which readily reacts with NO to 
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form peroxynitrite (ONOO-), resulting decreased bioavailability of NO and impaired 
vasodilatory responses (23).  Intracellular sources of ROS include peroxidases, xanthine 
oxidases, COX, lipoxygenases, the mitochondrial respiratory chain, heme-containing proteins, 
uncoupled NO synthases, and the NADPH oxidase (Nox) (24).  Endothelial cell express five 
types of  Nox subunits which includes Nox1, Nox2, Nox3, Nox4 and Nox5 (25).  Nox1, Nox2 
and Nox5 are considered as superoxide generating enzyme and promote endothelial dysfunction 
(25).  On the other hand, Nox4 is hydrogen per oxide (H2O2) generating enzyme and has the 
vasoprotective effect (25-28).  Vascular walls express high levels of Nox1, Nox2 and Nox4 (29).    
Nox1 is mainly expressed in large conduit vessels (30), whereas Nox2 is more highly expressed 
in resistance vessels (31).  
 
 
 
 
 
 
 
27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:   Release of endothelium-derived relaxation factors.  Activation of endothelial receptor 
(R) induces Ca2+ influx into the cytoplasm of the endothelial cell.  Upon binding with the 
agonists, inositol phosphate (IP3) increases which may contribute to the increased release of Ca2+ 
from sarcoplasmic reticulum (SR).  Ca2 + causes the activation of nitric oxide synthase (NOS) 
and releases endothelium-derived hyperpolarizing factor (EDHF) after interacting with 
calmodulin.  The elevated Ca2+ also leads to the formation of prostacyclin (PGI2) from 
archidonic acid (AA) by cyclooxygenase.  NO relaxes the smooth muscle by leading to the 
activation of cGMP from GTP.  PGI2 activates the formation of cAMP from ATP and causes the 
relaxation.  EDHF causes relaxation by opening of K+ channels and hyperpolarization.  Adapted 
from (32). 
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1.4.2 Prostacyclin (PGI2).  Endothelial prostanoids are produced by the phospholipases 
after releasing arachidonic acid from membrane-bound phospholipids.  Cyclooxygenase (COX) 
metabolizes arachidonic acid and gives rise to prostaglandin H2.  Prostaglandin H2 is then 
converted to several potent vasoactive prostanoids such as PGI2, prostaglandins E and F and 
thromboxane A2.  Among the prostanoids, PGI2 is the major prostanoid synthesized by 
endothelial cells.  PGI2 leads to the activation of adenylyl cyclase and an increase in the 
production of cyclic adenosine monophosphate (cAMP) by interacting with its GS-coupled PGI2 
receptor on the plasma membrane of vascular smooth muscle.  cAMP then relaxes the vascular 
smooth muscle by activating protein kinase A. which phosphorylates selected target proteins and 
results in smooth muscle relaxation.  Decreased secretion of PGI2 are closely related to the 
clinical and experimental models of diabetes (33, 34). 
1.4.3 Endothelium-derived hyperpolarizing factor (EDHF). EDHF, released from 
endothelium, is considered to be a substance and/or electrical signal that is produced or 
synthesized in the endothelium.  EDHF relaxes the VSMCs by hyperpolarizing smooth muscle 
cells and this is associated with K+ channels.  The EDHF-signaling pathways is not fully 
understood.  The contribution of EDHF in relaxation responses is dependent on the size of the 
vessel.  It is well established that EDHF is more prominent in the smaller arteries than the larger 
ones and is also an important regulator of vascular tone.  Two major pathways of EDHF are 
involved in vascular reactivity (35).  In the classical pathway, intracellular Ca2+ increases by 
shear stress or by local hormones such as ACh, bradykinin, substance P or histamine.  This 
elevated Ca2+ can activate two endothelial expressed potassium channels-small conductance 
calcium-activated potassium (SKCa) and intermediate conductance calcium-activated potassium 
channels (IKCa) and activates Na
+-K+-ATPase and/or inwardly rectifying K+ (KIR) channels, then 
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subsequently hyperpolarize smooth muscle cells (36-38).  The second pathway for EDHF does 
not involve the hyperpolarization of endothelial cells.  It is associated with the release of eclectic 
variety of EDHFs followed by the activation of large conductance Ca2+-activated K+ (BKCa) 
channels or ATP sensitive-K+ (KATP) channels, therefore hyperpolarizes the smooth muscle cells 
(39-41).  The relative importance of the relaxation factors differs with vessel size (42).  In large 
arteries and larger arterioles, NO is the major modulator of EDV.  Decreased bioavailability of 
NO is considered as the main marker of endothelial dysfunction in aorta.  NO, PGI2 and EDHFs 
are thought to be involved in mediating vascular tone of resistance arteries (43).  In diabetes, the 
contribution of EDHF to EDV were altered in small resistant arteries (44).  
1.5 Diabetes, CVD and Sex Differences 
Sex differences are the biological variances arise from variation in gene expression of sex 
chromosomes.  This may be further transformed by changes in sex hormones, resulting in 
modified sex specific function (45).  Earlier, majority of the clinical, epidemiological and 
experimental studies were conducted in male population and the outcomes were simply applied 
to females (46). The prevalence of CVD is higher in postmenopausal women compared to that of 
premenopausal women and the consequences are often worse compared with men.  Even though, 
the risk of developing CVDs in healthy premenopausal women are much lower than that in age 
matched men, women lose their sex-based protection after becoming diabetic (47-49). 
We have previously reported a sex differences in aortic and mesenteric arterial function 
in STZ- induced diabetic model and  hyperglycemic rats (50-52).  In those studies, we reported a 
predisposition to vascular injury of female rat aorta and mesenteric arteries in these pathological 
conditions.  Moreover, in epidemiological studies, it has been observed that the number of 
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women with impaired glucose tolerance (IGT) is 20% higher than in men and the total number of 
women with T2DM is 10% higher than in men (53) .  Thus, further studies are required to 
understand the underlying mechanism for these sex difference reported.  This may help in 
developing different therapeutic approaches and setting new therapeutic possibilities which may 
offer a route to improved care for women. 
1.6 Estrogen and Cardiovascular System 
Estrogens are a group of sex hormones that promote the development and maintenance of 
female characteristics in the human body (54).  Estrogen has favorable effects on vasculature, 
antioxidant activity, enhanced fibrinolysis and lipid profile.  Effects of estrogen in vascular 
function occurs through genomic and nongenomic mechanisms (55-57).  The genomic vascular 
effects involve modifications in expression of vascular cell gene by two distinct nuclear ERs 
(ERα and ERβ) and ultimately leads to an improvement of endothelial function and the responses 
to injury of blood vessels and development of atherosclerosis (55-57).  The nongenomic effect of 
estrogen occurs due to its interaction with plasmalemmal receptors in the endothelium and 
VSMCs.  For example, estrogen results in vasodilation by increasing NO production through 
activating eNOS or by inhibiting vascular contraction (58, 59).  Depending on the endothelial 
NO production and ion- channels, nongenomic vasodilator effects of sex hormones appear to 
have both endothelium-dependent and endothelium-independent mechanisms respectively (56, 
57, 60).  Sex differences in vascular reactivity partly related to the density of specific receptors 
as the expression of sex hormone receptors may vary depending on gonadal function, sex and 
degree of atherosclerosis.  Female arteries have higher amount of estrogen receptor (ER) than 
those of men (61).  Moreover, postmenopausal women and women with coronary artery disease 
have reduced number and activity of ERs in the vasculature (62, 63).  In diabetic women, 
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estrogen level decreases than those of nondiabetic women which results in progressive decline in 
progressive decline in glucose-stimulated insulin secretion and increase insulin resistance by 
reducing insulin sensitivity (63, 64). 
1.6.1 Estrogen and NO. Premenopausal women have elevated level of total NO than in 
men (65).  The differences in endothelial NO production may explain the sex differences in 
modulating vascular tone but the cellular origin of the increased NO in women is not well 
understood (64, 65). It is well established that estrogen has a major role in endothelial NO 
release (66-70).  One of the reasons for elevated eNOS may be due to the activation of genomic 
ERs (71).  In addition, estrogen can interact with specific ERs in endothelial cell membrane and 
also activate nongenomic signaling pathways, thus regulate vascular tone by producing NO (68, 
70).  Intracellular calcium concentration ([Ca2+]i) has a major role on the effect of estrogen in 
eNOS activation and NO production.  In the vascular endothelium, sex differences in the 
endothelial [Ca2+]i  regulation has been correlated to the estrogen effects on the Ca2+ handling 
mechanisms in the vascular endothelium (70, 72, 73).  Evidence suggests that estrogen can 
stimulate NO release and increases in [Ca2+]i by activating cell surface ERs in human endothelial 
cells.  It has also been suggested that the sensitivity of eNOS to [Ca2+]i may differ in male and 
female vasculature.  Estrogen can activate eNOS through the PI3K/Akt pathway by inducing 
phosphorylation, thus reduces the requirement of [Ca2+]i for activation (74).  The antioxidant 
effects of estrogen may also have a role on NO pathway.  In human umbilical vein endothelial 
cells, estrogen inhibited NADPH oxidase expression and the generation of reactive oxygen 
species (ROS) and peroxynitrate (ONOO-) (75).  The amount of superoxide (O2
•-) is higher in 
male aortic rings than in female rats (76).  Moreover, estrogen increases NO bioactivity and 
decreases ONOO- release by decreasing the generation of O2
•- in cultured bovine aortic 
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endothelial cells (77).  Therefore, estrogen administration may improve endothelial function and 
prevent oxidative stress by decreasing vascular tone and arterial pressure. 
1.6.2 Estrogen and PGI2. The production of COX products such as PGI2 may be 
augmented by estrogen (68) .  At physiological concentration, estrogen can upregulate the PGI2 
synthesis bovine fetal pulmonary artery and human umbilical vein endothelial cells (78).   
Studies have shown that the COX-2 pathway plays a specific role in estrogen-induced 
potentiation of cholinergic vasodilation in postmenopausal women (79).   However, it has been 
reported that estrogen-induced relaxation does not alter by the addition of indomethacin in 
coronary artery, suggesting that the release of prostanoids may not be involved in the estrogen-
induced coronary relaxation (80).  It has also been shown that estrogen may enhance the NO- 
mediated endothelium derived relaxation by modulating cross-talk between the NO synthase and 
COX pathways of vasodilation which is associated with a decrease in the COX component (81). 
1.6.3 Estrogen and EDHF. The differences in the endothelium-dependent 
hyperpolarization of VSMCs may be associated with the higher endothelium- derived relaxation 
in females than in males (82).  It has been suggested that ACh-induced vasorelaxation and 
hyperpolarization of mesenteric arteries are reduced in intact male and ovariectomized female 
rats compared with that in intact female rats.  Interestingly blocking of the K+ channels by 
apamin or charybdotoxin eliminated the differences in ACh-induced relaxation responses 
between male and female.  Furthermore, treatment with estrogen improved the hyperpolarizing 
response to ACh in ovariectomized female rats.  These data suggest that EDHF -mediated 
relaxation is attenuated in estrogen- deficient states (83, 84). 
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1.6.4 Estrogen and male vasculature. Estrogen also affects vascular function in males.  
The level of estrogen in males are dependent on androgen production.  In males, almost 80% of 
estrogen in plasma derives from aromatization of androstenedione and testosterone into estrogen.  
Furthermore, estradiol can stimulate ERs of endothelial and VSMCs which is produced directly 
in the male vasculature.   Interestingly, estrogen has been shown to improve endothelial function 
at low-dose in men with endothelial dysfunction, aromatase deficiency and diffuse 
atherosclerosis (85, 86).  Although estrogen is considered to be the major factor in sex-based 
differences in CVDs, the effect of other sex hormones such as androgen, progesterone and 
testosterone cannot be ignored.  It has been suggested that these sex hormones have role in 
regulating vascular tone, lipid profile and cell proliferation.  For example, studies have reported 
that both progesterone and testosterone have antiatherosclerotic effect and influence the release 
of EDRF from endothelial cells, inhibit proliferation of smooth muscle cells.  Furthermore, 
progesterone can increase high density lipoprotein and decrease LDL (87).  Effect of these sex 
hormone are not clearly understood and warrants further investigation. 
1.7 Study of Type 2 Diabetes and Type 2 Diabetic Rodent Model 
Metabolic diseases and the risk factors associated with the disease frequently occurs in 
combination such as diabetes, obesity, dyslipidemia, and hypertension.  Several hereditary 
animal models have been used to investigate these diseases which includes KK-Ay mouse, ob/ob 
mouse, db/db mouse, Zucker Diabetic Fatty (ZDF) rat, GotoKakizaki (GK) rat, Spontaneously 
Diabetic Torii (SDT) rat, OtsukaLong-Evans-Tokushima-fatty (OLETF) rat, and Spontaneously 
Hypertensive Rat (SHR).  In addition, genetically modified animals,chemical (e.g. streptozotocin 
(STZ), alloxan) and diet-induced (e.g., high fat, high fructose, high sucrose, high cholesterol) 
fructose, high fat, high cholesterol) experimental animal models have also been used widely (88, 
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89).  Type 2 diabetic rodent models have been available for many years.  There are several 
reasons for using rodent models of human disease which includes smaller size, shorter breeding 
time and inexpensive housing.  Due to the smaller size, rodent models can be used to design 
preventive strategies and treatments with minimal expense.  For the study of human type 2 
diabetes, variety of rodent models are commercially available.  Several factors are associated 
with human type 2 diabetes including the degree of obesity at disease onset, age of onset, and the 
degree of deterioration in beta cell function observed over the course of the disease.  All the 
potential characteristics of disease will not be manifested by a single individual.  Likewise, no 
single rodent model represents all possible pathologies associated with type 2 diabetes.  
Furthermore, due to the inherent species difference and methodologies used to breed rodent 
models, the ability of rodents to mimic accurately human type 2 diabetes is challenging.  
Therefore, there is an ongoing demand for novel models which would better resemble the 
pathologies of human disease.   
In human, obesity is primarily caused by polygenic mutation, but experimental studies of 
type 2 diabetes are conducted by using monogenic model of obesity.  The most commonly used 
monogenic rodent models of obesity have leptin signaling deficiency.  Major function of leptin is 
to induce satiety, therefore, deficiency in leptin signaling causes hyperphagia and subsequent 
obesity in these animals.  These models include the Lep ob/ob mouse, the Lepr db/db mouse and 
Zucker Diabetic Fatty rat.  These models are frequently used to test new therapeutic approaches 
for type 2 diabetes.  However, lack of leptin signaling leads to early onset of diabetes, infertility, 
severe hyperlipidemia, lack of insulin sensitizing effect and lipotoxic effects which are disparate 
to those seen in human type 2 diabetes. 
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Rodent models with polygenic origin of obesity may represent more accurate model of 
human disease states.  Although, there are different polygenic rodent models of diabetes, glucose 
intolerance and obesity exist, but unlike the monogenic models, there are no wild-type controls.  
In addition, biasness towards male sex is more extreme in these models (90).   
The NZO mouse is generated by selective breeding, has a polygenic origin of obesity.  It 
has deficiency in leptin transportation across the blood brain barrier, resulting in hyperphagia and 
obesity due to the lack of centrally mediated actions of leptin.  In addition, NZO mice have early 
onset of obesity and poor fertility (89).  
Another new model of type 2 diabetes is Spontaneously Diabetic Torii Lepr f a (SDT 
fatty) rats which are generated by introducing the fa allele of the ZDF rat into the SDT rat 
genome.  Both sexes of SDT fatty rats became overtly obese and showed a significant 
hyperphagia (91). 
In OLETF rat, diabetes is induced by two mutations which are the particular concern 
regarding their non-human-like characteristics. This model of rats become hyperphagic due to 
the mutation in CCK-A receptor subtype.  Also, they have x-linked mutation (obd-1) which 
results in the diabetes phenotype in males but female rats do not develop diabetes. In addition, to 
manifest diabetes, OLETF rats required testosterone unlike humans. 
It is very important to consider the lean animal model of type 2 diabetes in the study as 
not all the type 2 diabetic patients exhibit obesity.  The Goto Kakizaki rats resembles several 
aspects of human type 2 diabetes but does not become obese unlike most of the human type 2 
diabetic patients.  This lean model of type 2 diabetes characterized by impaired insulin secretion 
and glucose intolerance.  Aberrant beta cell function and/or mass results in defective glucose 
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metabolism and insulin resistance is not the main reason for initiating hyperglycemia in this 
model (92) .  Finally, the major disadvantage with most of these models is the fact that typically 
female animals do not develop diabetes, or they develop diabetes under environmental stressed 
conditions.  High fat and high sugar diet can induce hyperglycemia in ZDF female rats and in 
Wistar female rats required high sucrose diet to induce hyperglycemia.  In contrast, rate of 
developing diabetes in human females is slightly higher than males (89). 
1.7.1 Need for a novel model of type 2 diabetes. To compensate the deficiencies of 
existing models, it became very crucial to develop novel models of type 2 diabetes.  An ideal 
model should have the combination of two primary defects observed in human type 2 diabetes, 
i.e. adult onset of polygenic origin of obesity with insulin resistance, and defect in beta-cell 
compensation for insulin resistance.  An ideal model should develop diabetes in both sexes at 
approximately equal rates and would not require any gene mutations to induce obesity or 
diabetes.  
1.8 Statement of Research Problem and Hypothesis 
The prevalence of developing CVD is lower in premenopausal women compared to age 
matched man (1-3).  This lower risk is related to the presumptive cardioprotective effects of 
female sex hormones, estrogen in particular.  However, diabetic premenopausal women not only 
lose this sex-based cardiovascular protection, they also experience a higher risk of CVDs 
compared to diabetic men (7-9).  Several lines of evidence suggest that endothelial dysfunction 
represents early steps in the development of vascular complications in diabetes, and 
hyperglycemia is the central initiating factor for those complications.  Nonetheless, there is 
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insufficient evidence to establish the timeline of the loss of this female-specific protection in 
premenopausal patients with diabetes.  
With the increasing prevalence of type 2 diabetes, creating an effective preclinical model 
of T2DM has become crucial for the study of disease prevention and treatment.  Dr. Havel and 
colleagues at University of California (UC) Davis, developed a rat model of type diabetes that 
has been validated in several studies including all features of  type 2 diabetic pancreatic, hepatic 
and gastrointestinal dysfunction (93-99). UCD-T2DM rat model more closely resembles the 
pathophysiology of human T2DM.  Till now there is no data on aortic function of UCD-T2DM 
rats.  Previously we reported sex differences in the vasodilation of rat or rabbit aorta after acute 
exposure to high glucose (100).  We also observed sex-based differences in impaired EDV of 
aorta and mesenteric arteries in STZ- induced type 1 diabetic rats (52).  However, the 
pathophysiology of T1DM differs from T2DM.  
Our hypothesis is aortic endothelial function is altered in UCD-T2DM rats.  Furthermore, 
we hypothesize that there is a sexual dimorphism in aortic endothelial function of UCD-T2DM 
rats.  If our data show the loss of vascular protective effect in diabetic females; we will 
investigate the timeline of its loss by examining EDV in pre-diabetic UCD-T2DM rats.  
Particularly, we will examine the effect of female sex hormones (specifically estrogen) by 
replacing estrogen following removal of ovaries. 
1.9 Specific Aims 
1) To investigate whether the aortic reactivity is altered in a novel and validated model of 
type 2 diabetes, UC Davis-T2DM mellitus (UCD-T2DM) rats with respect to sex; 
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2) To determine whether sex and type 2 diabetes altered the relative contributions of 
PGI2, NO and EDHF to aortic endothelial function in male and female UCD-T2DM rats; 
3) To determine the underlying mechanisms of sex-based differences in the vascular 
effects by studying expressions of specific proteins that are associated with arterial function 
(eNOS, peNOS, Nox1- and Nox4-dependent NADPH oxidase, as well as IKCa and SKCa 
channels) and insulin signaling (Akt, pAkT, IRS-1 and IRS-2); 
4) To investigate the effects of 17β-estradiol (E2) on aortic function in ovariectomized 
UCD-T2DM rats at the prediabetic stage; 
5) To determine the effects of 17β-estradiol (E2) on the underlying mechanisms of 
vascular effects by studying expressions of specific proteins that are associated with aortic 
function (eNOS, Nox1- and Nox4 dependent NADPH oxidase). 
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Chapter 2: Study I:  Sex Differences in Aortic Reactivity of UC Davis Type 2 Diabetes 
Mellitus (UCD- T2DM) Rats: A Shift in the Relative Importance of Endothelium 
Dependent Relaxation Factors (EDRF) 
2.1 Introduction 
The prevalence of T2DM is on the rise worldwide, thereby creating an effective 
preclinical model of T2DM has become crucial for the study of disease pathogenesis, prevention, 
and treatment.  Among the existing rodent models of T2DM (as described in Section1.7), most 
commonly used rodent models are Zucker diabetic fatty (ZDF) rat, Otsuka Long Evans 
Tokushima fatty (OLETF) rat, and the db/db mouse.  They all exhibit obesity-associated insulin 
resistance and impaired β- cell function which results from a monogenic mutation.  Even though 
these established models have generated a great deal of useful data, but they have several 
disadvantages.  Obesity phenotype is the common problem with these rodent models of T2DM.  
In humans, obesity and insulin resistance is adult onset and polygenic in origin, monogenic 
mutations are not very common to onset diabetes.  Thus, effective translation of research to 
clinical type 2 diabetes can be challenging (63).   
Owing to the difference in the etiology, our collaborators at UC Davis, Dr.Havel et.al 
have developed a new rat model of T2DM that more closely models the human T2DM. This 
model is developed by crossing obese insulin-resistant Sprague-Dawley (OSD) rats with ZDF-
lean rats, both have only one of the primary defects associated with type 2 diabetes and each are 
nondiabetic.  ZDF-lean rats have defect in pancreatic β-cell insulin production and do not have 
the leptin receptor mutation unlike ZDF rats (101), results in diabetes only in the presence of 
insulin resistance.  On the other hand, OSD rats, which were originally obtained from Charles 
River Laboratories (Wilmington, MA) differ from healthy SD animals as the OSD rats gain 
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weight more rapidly than SD rats purchased from a different vendor.  The OSD rats do not 
develop diabetes due to strong β-cell compensation, exhibit adult-onset polygenic obesity and 
hyperphagia and more metabolically efficient than normal weight animals (102).  After using 
selective breeding, subsequent generations successfully resulted in diabetes in both male and 
female animals.  UCD-T2DM rat exhibit adult-onset obesity, impaired glucose tolerance, insulin 
resistance, β-cell decompensation, and preserved fertility in both sexes.  Therefore, this models 
more closely mimics human T2DM.  There is no data on the aortic function of UCD-T2DM rats.  
Thus, our preliminary aim was to investigate whether the aortic function is impaired and sex 
differences exist in the development of abnormal vascular responses in male and female UCD-
T2DM rats.  
Endothelial dysfunction is an early sign of diabetic vascular diseases.  Endothelial 
dysfunction can be defined as a reduced EDV to vasodilators, such as ACh and bradykinin, or 
flow-mediated vasodilation.  EDV is considered as a reproducible parameter to investigate 
endothelial function under various pathological conditions (17).  In diabetes, enhanced (103), 
impaired (104) and preserved (105)  EDV have been reported. EDV is largely depends on 
EDRFs, such as NO, PGI2 and EDHFs.  
The relative contribution of different EDRFs on EDV varies between the size of arteries 
(106) and vascular beds (107).  NO has been considered as a major contributor of EDV in large 
conduit arteries (108), whereas EDHF plays the predominant role in small resistant arteries 
(109).   
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Different pathological conditions can alter the relative contribution of various EDRFs to EDV.  
Therefore, another aim of our study was to investigate the relative contribution of EDRFs in 
EDV of UCD- T2DM male and female rats.  
2.2 Material and Methods 
2.2.1 Chemicals. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), and dissolved in water, unless otherwise stated. 
 2.2.2 Animals and experimental design. Rats were housed and bred in the animal 
facility in the Department of Nutrition at the University of California, Davis.  All animal 
protocols were approved by the Animal Care Committee of the University of the Pacific and 
University of California Davis Institutional Animal Care and Use Committee and complied with 
the Guide for the Care and Use of Laboratory Animals: Eighth Edition (US National Institutes of 
Health 2011) and with ARRIVE guidelines.  Rats were maintained with water and standard 
rodent chow food ad libitum at constant humidity and temperature, with a light/dark cycle of 12 
h.  After acclimation for 1 week, animals were euthanized for experiments using carbon dioxide 
as euthanasia agent, according to the recommendations from the 2013 AVMA Guidelines on 
Euthanasia (110) and the NIH Guidelines for the Care and Use of Laboratory Animals: Eighth 
Edition (US National Institutes of Health 2011).  
In the present study, male and female UCD-T2DM rats were used.  Diabetic phase was 
determined by measuring blood glucose level for three subsequent measurements using a 
standard glucose test meter (OneTouch, LifeScan, CA).  Animals were considered diabetic when 
nonfasting blood glucose levels were higher than 300 mg/dl.  Age-matched male and female 
non-obese and non-diabetic SD rats (Simonsen Laboratories, Gilroy, CA) were employed as 
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controls for UCD-T2DM rats.  All animals were average 19-20 weeks old.  The diabetic animals 
used in the study were diabetic for about 35± 2.7 (males) and 31±3.1 (females) days.   
2.2.3 Measurement of metabolic parameters in the plasma. Blood glucose were 
measured in 12-h fasted rats using standard glucose test meter (OneTouch, LifeScan, CA) and 
triglycerides were measured by using an Accutrend Plus System (hand-held point-of-care device) and 
specific test strips (Roche Farma, Barcelona, Spain) with a drop of blood collected from the tail vein.  
Blood samples were collected from intracardiac puncture and obtained in tubes containing heparin as 
an anticoagulant.  Plasma was obtained by centrifugation at 10,000xg for 5 min at 4°C and stored at -
80°C until used.  Insulin levels were determined in plasma samples by using ELISA kits according to 
the manufacturer’s protocol (Spi Bio, Montigny Le Bretonneux, France).  Insulin sensitivity index 
(ISI) was determined from fasting plasma glucose and insulin using the following formula:  
ISI = [2/ (blood insulin (nM) x blood glucose (μM) + 1]. 
2.2.3.1 HbA1C measurement. HbA1c is glycated hemoglobin (A1c), which identifies 
average plasma glucose concentration.   In Particular, the test measures the percentage of blood 
glucose attached to the hemoglobin.  HbA1c can also be measured using point-of-care 
technology, such as the Bayer A1cNow test kit.  A1cNow test kit consists of a monitor and a 
sample dilution kit.  Blood sample was collected after sacrificing the animal to measure HbA1c.  
The diluted sample was mixed and added to the monitor.  After adding the sample, the monitor 
begins the analyze and results will be displayed in the display window after 5 minutes. 
General range of HbA1c : 
• An A1C level < 5.6 percent is considered normal 
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• An A1C level between 5.6 and 6.4 percent is considered pre-diabetes 
• An A1C level > 6.5 percent on two separate tests indicates type 2 diabetes 
2.2.4 Measurement of arterial tension. The thoracic aortas were cut into 2mm rings 
after being excised and cleaned off adhering connective tissues.  To measure isometric tension, 
the rings were suspended horizontally between two stainless steel hooks in individual organ 
baths containing 20 ml of Krebs buffer (in mM: 119 NaCl, 4.7 KCl, 1.18 KH2PO4, 1.17 MgSO4, 
24.9 NaHCO3, 0.023 EDTA, 1.6 CaCl2, and 6.0 glucose) at 37°C bubbled with 95% O2 and 5% 
CO2.  Isometric tension was continuously monitored with a computer-based data acquisition 
system (PowerLab; ADInstruments, Colorado Springs, CO).  To develop a stable basal tone, 
aortic rings were equilibrated under 1g resting tension for 40 min.  Rings were stimulated two 
times with 80mM KCl every 20 min until maximum contraction was achieved.  The ability of 
acetylcholine (ACh, 10 μM) to induce relaxation of phenylephrine (PE, 2 μM) pre-contracted 
vessels was taken as evidence for the preservation of an intact endothelium.  For the relaxation 
studies, we used an equal submaximal concentration of PE (2 μM) in both males and females. 
2.2.4.1 Relaxation responses to ACh. Aortic rings were precontracted with PE (2 µM), 
which represented a concentration that produced 80% of the maximal effect (EC80).  The 
concentration response curves (CRC) were obtained by the addition of increasing concentrations 
of ACh (10-8 to 10-5 M).   
The first CRC was obtained by the addition of increasing concentrations of ACh (10-8 to 
10-5 M).   Tissue was washed 2-3 times with Krebs solution to allow it to return to basal tone.  
After it reached the basal tone, indomethacin was added (Indo; 10 μM; dissolved in DMSO), a 
COX inhibitor for 20 min.  The rings were again precontracted with PE and the second CRC to 
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ACh was generated.  The third CRC to ACh in PE-precontracted rings was obtained after 
incubation with Indo and 1H- [1,2,4] oxadiazolo [4,3-a] quinoxalin-1-one (ODQ; 10 µM), an 
inhibitor of soluble guanylate cyclase (sGC) for 20 min.  Finally, the fourth CRC to ACh was 
obtained after incubation with a combination of Indo, ODQ and N-nitro-L-arginine (L-NNA; 100 
µM), a nonselective NO synthase (NOS) inhibitor for 20 min.  
The contribution of K+ to ACh-induced relaxation was assessed in aortic rings by 
obtaining the CRC to ACh before and after incubation for 30-min with tetraethylammonium 
(TEA; 2mM), a nonselective K+ channel blocker; 1-[(2-chlorophenyl)(diphenyl)methyl]-1H-
pyrazole (TRAM-34; 1 µM), a selective blocker of the intermediate-conductance Ca2+ activated 
K+ (IKCa) channel; apamin (1 µM), a small-conductance Ca
2+ activated K+ (SKCa) channel 
inhibitor.  Tissues were washed with Krebs buffer between each concentration response curves to 
allow the rings to return to basal tone. 
2.2.4.2 Relaxation responses to Sodium Nitroprusside (SNP). Responses to SNP (10-9 to 
10-5 µM), a NO-donor, were obtained in the endothelium denuded aortic rings pre-contracted 
with PE (2 µM) taken from all experimental groups. 
2.2.4.3 Contractile responses to PE. The constrictor CRC to PE (10-8 to 10-5 M) were 
generated before and after incubation with Nω-Nitro-L-arginine methyl ester (L-NAME, 200 
μM), a NOS inhibitor in the presence of indomethacin (Indo, 10 μM, dissolved in DMSO), a 
COX inhibitor.  Between each CRC, tissues were washed with Krebs buffer to allow the rings to 
return to the basal tone.  A vehicle-only (no drugs present) study was performed simultaneously 
in aortic rings from the same animal (Data not shown). 
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2.2.4.4 Western blot analysis.  
2.2.4.4.1 Preparation of total protein extracts. Aortic tissue samples were micronized 
through freezing with liquid nitrogen and grinding with a mortar (111).  To obtain total protein 
extract, samples were incubated with RIPA buffer (Sigma-Aldrich, St. Louis, MO) containing 
Protease Inhibitor Cocktail (UltraCruz, Santa Cruz Biotechnology, Dallas, TX) for 1.5 h at 4°C 
and centrifuged at 1500xg for 15 min at 4°C, and supernatants were collected.  Protein 
concentrations were by the bicinchoninic acid assay (BCA Assay). 
Protein (20–30 µg) was subjected to Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) electrophoresis.  Proteins were then transferred to 0.45 µm 
Nitrocellulose Membranes (Bio Rad Laboratories Inc., Hercules, CA), blocked for 1 h at room 
temperature with 5% w/v BSA in 0.1% Tween 20-Tris-buffered saline, and incubated overnight 
at 4°C with primary antibodies.  Primary antibodies for p-V-akt murine thymoma viral oncogene 
homolog-2 (Akt) (Ser473), total Akt, p-endothelial NO synthase (eNOS) (Ser1177), endothelial NO 
synthase (eNOS), insulin receptor substrates IRS- 1, IRS-2 were supplied by Cell Signaling 
(Boston, MA).  Antibodies against Nox1, Nox4, KCNN3 (SKCa) and KCNN4 (IKCa) were 
obtained from Abcam (Cambridge, MA).  Incubation with secondary antibody (LI-COR donkey 
anti-Rabbit IgG IRDye 680 or anti-mouse IgG IRDye 800CW, 1: 10,000) was performed in the 
blocking buffer for 1 h at room temperature.  Before analyzing, the membrane was washed four 
times with TBS containing 0.1% Tween-20.  Detection was done by using a LI-COR Odyssey 
imaging system (Lincoln, NE).  Uniformity of the protein loading was confirmed by incubating 
the blots with GAPDH and β- actin (Cell Signaling, Boston, MA) as a control. 
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2.2.4.5 Statistical analysis. All values were expressed as mean of n values ± standard 
error of the mean (SEM). Here, n denotes data from one rat.  Relaxation responses to ACh- and 
SNP were calculated as the percentage of relaxation from maximum PE contraction at each 
concentration.  Similarly, the recorded increase in the force of contraction was calculated as the 
percentage of maximum contraction obtained with PE at the highest dose.  The concentration of 
the agonist, which produced half of the maximum effect (Emax) was expressed as EC50 and 
calculated by a sigmoidal dose-response model (for variable slope) using GraphPad Prism 7 
(GraphPad Software Inc., San Diego, CA).  The sensitivity of the agonists was expressed as pD2 
values (-log [EC50]), which were normally distributed.  The area under the curve (AUC) was 
determined using GraphPad Prism 7 with trapezoidal technique.  To compare the effect of 
different drugs such as TRAM-34 on the ACh response, the ACh results were expressed as 
differences of area under the concentration response curve (ΔAUC) in control (absence of 
TRAM-34) and experimental (presence of TRAM-34) condition.  Comparison of CRCs between 
two groups was done using two-way ANOVA, with one factor being concentration and the other 
being groups (male vs female and control vs. diabetic).  When the ANOVA test returned P 
<0.05, post hoc analysis using Bonferroni’s or Tukey’s test was performed.  Comparison of 
CRCs in a pre/post-test format within a group was done using two-way ANOVA with repeated 
measures.  Student's unpaired t-test was used for comparisons of two group means.  A 
probability value of less than 5% (P<0.05) was considered significant. 
2.3 Results 
2.3.1 Effects of sex and type 2 diabetes on metabolic parameters. Body weights of 
both male and female diabetic rats were significantly higher compared with the respective non-
diabetic controls (Table 1).  Accordingly, the adipose tissue weight, as well as their ratios to the 
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body weight were significantly higher in diabetic rats than those in non-diabetic control groups 
in both sexes.  Moreover, male and female UCD-T2DM rats had higher triglyceride level in 
plasma than that of non- diabetic controls.  However, when compared to male UCD-T2DM rats, 
female UCD-T2DM rats had significantly higher circulating triglyceride level.  Also, diabetic 
groups showed increase in adiposity.  Interestingly, female diabetic had higher adiposity 
compared to male diabetic rats, respectively.   
The glycosylated haemoglobin A1c (HbA1c) test indicates average of blood glucose level 
for the past two to three months of study.  Both glucose and HbA1c levels were higher in male 
and female diabetic rats compared to their respective non- diabetic controls.  The plasma insulin 
concentration was significantly higher in female diabetic rats compared with those in non-
diabetic female controls (Table 1).  However, there was no difference in plasma insulin level in 
male diabetic rats when compared with their respective controls. 
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Table 1:  Body weight and adipose weight, blood glucose levels, HbA1c, and other metabolic 
parameters of male and female control and diabetic rats 
 
  n Male Control Male Diabetic Female 
Control 
Female 
Diabetic 
Body Weight 
(g) 
19-22 306.99±12.09 514.04±14.98* 211.77±3.80 402.79±5.85* 
Adipose Tissue 
(g) 
19-22 1.32±0.21 10.89±0.87* 1.56±0.22 14.80±1.68*# 
Adipose Tissue/ 
Body Weight 
(g) 
19-22 0.0045±0.0006 0.02±0.001* 0.007±0.001 0.037±0.004*# 
Triglyceride 
(mmol/l) 
19-20 1.64±0.12 2.15±0.18* 1.45±0.06 3.64±0.27*# 
Blood Glucose 
(mg/dl) 
19-20 143.33±6.26 361.6±29.81* 152.17±9.75 357.19±29.21* 
HbA1c level 14-18 4.23±0.10 11.07±0.58* 4.40±0.06 10.09±0.58* 
Insulin (ng/ml) 8-10 0.91±0.52 0.96±0.25 0.49±0.14 5.71±1.91*# 
ISI 8-10 1.35±0.13 0.60±0.15* 0.89±0.23 0.10±0.03*# 
Data are expressed as mean ± SEM. *p<0.05 (vs. control, same sex), #p<0.05 (vs. male, 
respective group), using Student’s unpaired t-test.  Insulin sensitivity index (ISI) = [2/ (blood 
insulin (nM) x blood glucose (μM) + 1].  HbA1c = glycated hemoglobin (A1c). 
 
2.3.2 Effects of sex and type 2 diabetes on insulin signaling. Insulin sensitivity index 
(ISI), inversely indicative of insulin resistance, was significantly lower in both diabetic groups 
regardless of sex.  However, when compared to male UCD-T2DM rats, female UCD-T2DM rats 
had lower ISI level (Table 1), suggesting that insulin signaling may be impaired in both diabetic 
groups. Therefore, we analyzed the expression of main insulin signal transducers, insulin 
receptor substrate-1 (IRS-1) and insulin receptor substrate-2 (IRS-2) in aortic tissue.  Our results 
showed that IRS-1 expression was significantly reduced in both diabetic groups (by 0.5 fold in 
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male diabetic group and by 0.4 fold in female diabetic group), with a significantly lower 
expression in female diabetic than male diabetic animals (Figure 2A).  On the other hand, the 
protein expression of IRS-2 was reduced by 0.5 fold only in female diabetic group compared to 
non-diabetic female control group.  IRS-2 expression level was not altered in male by disease 
condition (Figure 2B).  The expression of Akt, one of the main transducers of insulin signaling 
downstream of IRS was also analyzed in aortic tissue.  The ratio of p-Akt/total Akt was 
significantly reduced in the aorta of both male and female diabetic groups ( by 0.4 fold and by 
0.5 fold respectively) compared to their respective control group, whereas total Akt protein 
remained unaltered in UCD- T2DM rats, irrespective of sex (Figure 3). 
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Figure 2:  Protein levels of aortic insulin receptor substrate IRS-1 (A) and IRS-2 (B) from the 
samples of male and female control and diabetic rats.  IRS-1 (A) and IRS-2 (B) were quantified 
by densitometry and normalized to corresponding beta actin.  Values are represented as mean± 
SEM.  Each bar represents the values obtained from n=5-6 animals per group.  To show 
representative bands, images from different parts of the same gel have been juxtaposed, indicated 
by white dividing lines.  Capped lines indicate significant differences between two groups 
(P<0.05), as analyzed by Student’s unpaired t-test. 
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Figure 3:  Protein levels of aortic phosphorylated/total V-akt murine thymoma viral oncogene 
homolog-2 (Akt) from the samples of male and female control and diabetic rats.  pAkt/Akt were 
quantified by densitometry and normalized to corresponding Beta Actin.  Values are represented 
as mean± SEM.  Each bar represents the values obtained from n=5-6 animals per group.  To 
show representative bands, images from different parts of the same gel have been juxtaposed, 
indicated by white dividing lines.  Capped lines indicate significant differences between two 
groups (P<0.05), as analyzed by Student’s unpaired t-test.  
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2.3.3 Effects of sex and type 2 diabetes on relaxation responses to ACh. CRC to ACh 
were obtained to evaluate the effect of type 2 diabetes on the receptor-mediated endothelium-
dependent release of NO or stimulated release of NO.  Diabetes slightly but significantly 
impaired the relaxation responses to ACh in aortic rings from female diabetic group compared to 
non- diabetic female controls (Figure 4B).  The Emax but not the sensitivity (as assessed by -log 
[EC50] (pD2)) of aortic rings to ACh were reduced in female diabetic group compared to their 
respective non- diabetic control group (Table 2).  On the contrary, a potentiated relaxation 
response to ACh was observed in male diabetic group (Figure 4A).  Both the Emax and pD2 of 
aortic rings to ACh were significantly enhanced in the aortic rings of male diabetic group 
compared with their respective non-diabetic controls (Table 2). 
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Figure 4:  Relaxation responses to cumulative concentrations of acetylcholine (ACh, 10-8 to 10-5 
M) in intact aortic rings precontracted with phenylephrine (PE, 2µM) from male (A) and female 
(B) control and diabetic rats.  Data are expressed as means ±SEM. n=6-12 animals per group.  *P 
< 0.05 between two groups analyzed using 2-way ANOVA followed by Bonferroni’s post hoc 
test.  
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Table 2:  pD2 and Emax to acetylcholine (ACh) in aortic rings from male and female control and 
diabetic rats 
 
ACh n pD2 Emax % 
Male Control 12 6.57± 0.10 81.14±1.63 
Male Diabetic 11 7.14±0.057* 94.04±0.98* 
Female Control 6 7.20±0.10# 94.72±1.90# 
Female Diabetic 7 7.07±0.11 87.31±2.31*# 
Data are expressed as mean ± SEM; n, number of rats per group.  *p<0.05 (vs. control, 
same sex), #p<0.05 (vs. male, respective group), analyzed using Student’s unpaired t-test.  
 
 
 
 
 
2.3.4 Effects of sex and type 2 diabetes on relative contributions of EDRFs to ACh-
induced relaxation. The relative contributions of PGI2 and NO to vasorelaxation induced by 
ACh were estimated by sequentially inhibiting COX, sGC, and NOS.  Specifically, EDV to ACh 
(10-8 to 10-5 M) in rat aortic rings precontracted with PE (2 µM) was obtained before and after 
pretreatment with Indo (10 µM), followed by addition of ODQ (10 µM) and L-NNA (100 µM).  
When ODQ was added, the EDV reduction is thought to represent the impact of C-GMP in EDV 
(112).   Addition of L- NNA represent the impact of NO, and the remaining EDV to ACh is 
referred to as the L-NNA/Indo-insensitive component, or EDHF-type relaxation (113, 114). 
The administration of Indo to block COX activity had no apparent effects on pD2 and 
Emax to ACh, regardless of sex or diabetes.  Moreover, the ΔAUC, defined as difference in the 
area under the curve between the ACh-CRC before and after Indo, were not different between 
UCD-T2DM groups and respective non- diabetic control groups, in both sexes (Figure 5, Table 
3).  In both males and females, the addition of ODQ substantially blocked the remaining 
55 
 
relaxation in all experimental groups.  However, a significant relaxation response was remaining 
in male diabetic group compared with the non-diabetic control and female diabetic animals 
(Table 3).  ΔAUC between the ACh-CRC before and after ODQ in the presence of Indo did not 
change in any of the diabetic group compared with their respective control.  Finally, in females, 
addition of L-NNA to block NO synthesis completely abolished the remaining Indo- and ODQ 
resistant vasorelaxation in both control and diabetic animals (Figures 5C & 5D).  In males, 
however diabetic group showed a significant remaining vasorelaxation compared with the non-
diabetic control animals after blocking NO synthesis with L-NNA (Figures 5A & 5B).  ΔAUC 
between the ACh-concentration response curve before and after L-NNA was significantly 
elevated, suggesting a role of NO independent (possibly EDHF) relaxation responses in male 
diabetic animals (Table 3).  Therefore, from this point we continued our investigation using male 
groups to further study the contribution of EDHF in ACh- induced relaxation responses.  
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Figure 5: Effects of inhibiting cyclooxygenase, soluble guanylyl cyclase and nitric oxide 
synthase on acetylcholine (ACh)-induced vasorelaxation in aortic rings taken from male control 
(A), male diabetic (B), female control (C) and female diabetic (D) rats.  ACh relaxation was 
measured in the presence of indomethacin (Indo ;10 µM), followed by addition of ODQ (10µM), 
and then with N-nitro-L-arginine (L-NNA;100µM).  Data are expressed as means ± SEM.  *P 
<0.05 vs. no drug; #P < 0.05 vs. Indo; analyzed using 2-way ANOVA with repeated measures 
followed by Bonferroni post hoc test (n=5-8 per group).  Light grey shaded area: Contribution of 
EDHF to EDV. 
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Table 3:  ΔAUC, pD2 and Emax to acetylcholine (ACh) in rat aortic rings from male and female 
control and diabetic rats 
 
A comparison of the ΔAUC, sensitivity (pD2) and maximum response (Emax) to acetylcholine in the 
absence (no drug) or in the presence of indo, indo+ODQ, and indo+ ODQ+L-NNA in aortic rings 
from male and female control and diabetic rats.  Data are expressed as mean ± SEM. *P<0.05 (vs. 
control, same sex), #p<0.05 (vs. male in respective group) (Student’s unpaired t-test);
 aP<0.05 vs. no 
drug control within each group, bP<0.05 vs. indo within each group (Student’s paired t-test) , n= 5-8 
per group.  ND, not determined. 
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2.3.5 Effects of type 2 diabetes on the relative contributions of K+ channels to ACh-
induced relaxation responses in male rats. In order to investigate the contribution of K+ 
channels in vasorelaxation in male groups, ACh responses were measured before and after 
incubation of aortic rings with TEA (a nonselective K+ channel blocker).  Incubation with TEA 
blunted the relaxation response to ACh in both male diabetic and control groups (Figures 6A & 
6B).  However, the ΔAUC between the ACh-CRC before and after TEA was higher in diabetic 
group suggesting that the inhibitory effect TEA on vasorelaxation was greater in diabetic group 
compared with their non-diabetic control group (Table 4).  
Next the contribution of specific calcium-activated K+ channels were evaluated by 
incubating the aortic rings with the selective blockers, TRAM 34 (IKCa blocker) and Apamin 
(SKCa blocker).  Addition of TRAM 34 significantly reduced the pD2 and Emax to ACh in male 
diabetic group compared with the nondiabetic control animals (Figures 7A & 7B).  Similarly, 
ΔAUC between the ACh-concentration response curve before and after TRAM-34 was 
significantly higher in diabetic group compared with the control animals (Table 4).  However, 
blocking of SKca channels by addition of Apamin had no apparent effect on pD2 and Emax to ACh 
in male control and diabetic groups (Figures 8A and 8B).  Consequently, the protein expression 
level of IKca and SKca channels were analyzed in the aortic tissues using western blot.  Western 
blot analysis revealed that the expression of both SKca and IKca were significantly increased (by 
10.0-fold and by 2.0-fold, respectively) only in the aortic tissue from male diabetic rats (Figures 
9A & 9B). 
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Figure 6: Effects of inhibiting calcium activated K+ channels on ACh-induced vasorelaxation in 
aortic rings taken from male control (A) and diabetic (B) rats.  Concentration response curves for 
ACh was measured before and after treatment with TEA (2mM).  Data are expressed as mean ± 
SEM. *P <0.05 vs. before TEA; analyzed using two-way ANOVA with repeated measures 
followed by Bonferroni post hoc test, n=6-8 per group.  Light grey shaded area: Contribution of 
calcium activated K+ channels to endothelium-dependent vasodilation (EDV). 
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Figure 7: Effects of inhibiting intermediate-conductance Ca2+ activated K+ (IKCa) channels on 
ACh-induced vasorelaxation in aortic rings taken male control (A) and diabetic (B) rats.  
Concentration response curves for ACh were measured before and after treatment with TRAM-
34 (1uM).  Data are expressed as mean ± SEM. *P <0.05 vs. before TRAM-34; analyzed using 
two-way ANOVA with repeated measures followed by Bonferroni post hoc test, n=8-9 per 
group.  Dark grey shaded area: Contribution of intermediate-conductance Ca2+ activated K+ 
(IKCa) channels to endothelium-dependent vasodilation. 
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Figure 8: Effects of inhibiting small-conductance Ca2+ activated K+ (SKCa) channels on ACh-
induced vasorelaxation in aortic rings taken from male control (A) and diabetic (B) rats.  
Concentration response curves for ACh were measured before and after treatment with Apamin 
(1uM).  Data are expressed as means ± SEM; analyzed using two-way ANOVA with repeated 
measures followed by Bonferroni post hoc test, n=8-9 per group.  Dark grey shaded area: 
Contribution of small-conductance Ca2+ activated K+ (SKCa) channels to endothelium-dependent 
vasodilation. 
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Table 4:  ΔAUC, pD2 and Emax to acetylcholine (ACh) in rat aortic rings from male control and 
diabetic rats 
 
A comparison of the ΔAUC, sensitivity (pD2) and maximum response (Emax) to acetylcholine in 
the absence (no drug) or in the presence of TEA or TRAM-34 or Apamin in aortic rings from 
male control and diabetic rats. Data are expressed as mean ± SEM. *P <0.05 vs control, 
Student’s unpaired t-test; # P <0.05 vs No Drug in respective treatment group, Student’s paired t-
test, n=8-9 per group.  TEA, tetraethylammonium; TRAM-34, 1-[(2-chlorophenyl) 
(diphenyl)methyl]-1H-pyrazole. 
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Figure 9: Protein levels of aortic intermediate conductance potassium channel (IKCa) (A) and 
small conductance potassium channels (SKCa) (B) were measured from the samples of male 
control and diabetic rats.  Values are represented as mean± SEM.  Each bar represents the values 
obtained from n=5-6 animals.  To show representative bands, images from different parts of the 
same gel have been juxtaposed, indicated by white dividing lines.  Capped lines indicate 
significant differences between two groups (P<0.05), as analyzed by Student’s unpaired t-test. 
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2.3.6 Effects of sex and type 2 diabetes on relaxation responses to SNP. The smooth 
muscle sensitivity to NO was investigated by performing CRC to SNP (10-9 to 10-5 M) in 
endothelium-denuded aortic rings.  There was a significant rightward shift in the CRC to SNP in 
female diabetic rats compared with their controls (Figure 10B).   Diabetes significantly reduced 
only the sensitivity as assessed by pD2 values to SNP in aortic rings from female diabetic group 
compared with non-diabetic controls (Figure 10B and Table 5).  However, no significant 
differences in CRC to SNP was observed in male diabetic and control animals (Figure 10A and 
Table 5).  
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Figure 10: Relaxation responses to cumulative concentrations of sodium nitroprusside (SNP, 10-9 
to 10-5 M) in endothelium denuded aortic rings pre-contracted with phenylephrine (PE, 2 μM) 
from male (A) and female (B) control and diabetic rats.  Data are expressed as mean ± SEM. n= 
5-7 per group. 
 *P<0.05 between two groups analyzed using two-way ANOVA followed by Bonferroni’s post 
hoc test.  
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Table 5:  pD2 and Emax to sodium nitroprusside (SNP) in rat aortic rings from male and female 
control and diabetic rats 
 
SNP n pD2 Emax, % 
Male Control 5 8.06± 0.09 100.15±0.35 
Male Diabetic 6 8.19±0.13 101.46±1.41 
Female Control 6 8.50±0.07 104.34 ±3.29 
Female Diabetic 7 8.32±0.01* 100.18±0.45 
 
 
Data are expressed as mean ± SEM; n, number of rats per group. *P<0.05 (vs. control, same sex), 
analyzed using Student’s unpaired t-test. 
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2.3.7 Effects of sex and type 2 diabetes on contractile responses to PE. Contractile 
responses to α-adrenoceptor agonist (PE) were analyzed by measuring the CRC to PE (10-8 to 10-
5 M).  Both pD2 and Tensionmax to PE were significantly enhanced in diabetic groups compared 
with the non- diabetic control rats, regardless of sex (Figures 11A & 11B and Table 6).  
To indirectly measure the level of basal NO, CRC to PE (10-8 to 10-5 M) was performed 
in aortic rings before and after pretreatment with the NO synthase inhibitor, L-NAME (200 µM) 
in the presence of Indo (10 µM).  The changes in the contractile level to PE after addition of L-
NAME would reveal the effect of basal NO release on contraction (115, 116).  
Incubation of the aortic rings with L-NAME resulted in a significant increase of the 
contractile responses to PE in all experimental groups (Figure 12).  However, as indicated by 
ΔAUC (the difference in area under the curve between PE CRC before and after L-NAME) were 
lower in aortas of the diabetic rats compared with the control group, regardless of sex (Table 7).  
Furthermore, the basal NO level was significantly lower in male diabetic animals compared with 
female diabetic group as assessed by ΔAUC (Table 7). 
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Figure 11:  Concentration-response curves to phenylephrine (PE, 10-8 to 10-5 M) in intact aortic 
rings of male (A) and female (B) control and diabetic rats.  Data are expressed as mean ± SEM. 
n=5-7 per group.  *P<0.05 between two groups analyzed using two-way ANOVA followed by 
Bonferroni’s post hoc test. 
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Table 6:  pD2 and Tensionmax to phenylephrine (PE) in aortic rings from male and female control 
and diabetic rats 
Data are expressed as mean ± SEM; n, number of rats per group.  *P<0.05 (vs. control, same sex), 
analyzed using Student’s unpaired t-test. 
 
 
 
 
 
 
 
 
 
 
PE n pD2 
Tension max 
(g) 
Male Control 5 6.81±0.047 1.26±0.16 
Male Diabetic 5 7.19±0.09* 1.79±0.12* 
Female Control 5 6.78±0.08 1.04±0.13 
Female Diabetic 6 7.14±0.05* 1.53±0.16* 
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Figure 12: Contractile response to cumulative concentrations of phenylephrine (PE) in intact 
aortic rings from male control (A), male diabetic (B), female control (C) and female diabetic (D) 
rats.  Contraction to PE was measured before and after incubation with Nω-Nitro-L-arginine 
methyl ester (L-NAME, 200 μM).  Responses were performed in the presence of indomethacin 
(10 μM).   
Data are expressed as mean±SEM, with *P<0.05 vs. before L-NAME in all groups as analyzed 
using two-way ANOVA with repeated measures, n=5-8 per group. 
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Table 7:  ΔAUC, pD2 and Tensionmax to phenylephrine (PE) in aortic rings from male and female 
control and diabetic rats 
 
Data are expressed as mean± SEM. L-NAME, N-nitro-L-arginine methyl ester.  *P <0.05 
vs.control (Same sex), #P<0.05 vs male diabetic, Student’s Unpaired t-Test;  aP<0.05 vs before 
L- NAME, Student’s  paired t-test. n=6-8 per group. 
           
 
 
 
 
 
  Tensionmax,, g pD2 ΔAUC 
Male Control 
Before L-NAME 1.09±0.11 6.74±0.085 
239.10±5.00 
After L-NAME 2.47±0.29a 7.29±0.07a 
Male Diabetic 
Before L-NAME 1.66±0.17* 6.95±0.12 
103.66±18.15* 
After L-NAME 2.26±0.11a 7.46±0.099a 
Female Control 
Before L-NAME 0.93±0.17 6.76±0.077 
319.44±59.81 
After L-NAME 2.25±0.25a 7.21±0.11a 
Female Diabetic 
Before L-NAME 1.19±0.16 7.008±0.054* 
167.42±6.87*# 
After L-NAME 1.98±0.13a 7.35±0.059a 
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2.3.8 Effects of sex and type 2 diabetes on eNOS and Nox expression. To investigate 
the possible mechanisms underlying the alterations of the ACh responses in male and female 
diabetic rats, the protein expression of eNOS and NADPH oxidase (Nox) subunits, Nox1 and 
Nox4 were measured. Moreover, eNOS activation was measured by determining the level of 
peNOS.  Western Blot analysis revealed that the ratio of peNOS over total eNOS were 
significantly decreased in male diabetic group compared with the non- diabetic control rats.  
However, ratio of peNOS over total eNOS protein levels showed no significant difference 
between female control and diabetic groups (Figure 13). 
The expressions of Nox1 was significantly elevated in aortic tissues taken from diabetic 
groups, regardless of sex (by 1.5-fold in male diabetic and by 1-fold in female diabetic, Figure 
14A).  However, protein expression of Nox4 showed no significant differences among all 
experimental groups (Figure 14B). 
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Figure 13:  Protein levels of phosphorylated/ total eNOS in aortic samples from male and female 
control and diabetic rats.  Each bar represents the mean ± SEM of values obtained from n=5 
animals per group.  To show representative bands images from different parts of the same gel 
have been juxtaposed, which is indicated by white dividing lines.  Capped lines indicate 
significant differences between two groups (P<0.05), as analyzed by Student’s unpaired t-test. 
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Figure 14:    Protein levels of aortic Nox1 (A) and Nox4 (B) from the samples of male and 
female control and diabetic rats.  Values are represented as mean± SEM.  Each bar represents the 
values obtained from n=4-5 animals per group.  To show representative bands, images from 
different parts of the same gel have been juxtaposed, indicated by white dividing lines.  Capped 
lines indicate significant differences between two groups (P<0.05), as analyzed by Student’s 
unpaired t-test. 
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2.4 Discussion 
This study is the first report on the aortic function of a well-characterized and validated 
model of T2D, the UCD-T2DM rat.  Furthermore, it reveals a sex difference in the aortic 
reactivity of this model.  Obesity and insulin resistance are some of the important features of 
T2D results from monogenic mutation in commonly used animal models.  However, obesity is 
rarely initiated by monogenic mutations in humans, therefore UCD-T2DM rat model is a 
polygenic model of T2D which more closely resembles the pathophysiology of diabetes in 
humans. 
Our data shows that both male and female diabetic rats had higher body weight and 
hyperglycemia compared with non-diabetic control rats.   Moreover, female diabetic group 
exhibited higher adiposity, hyperinsulinemia and higher triglyceride level than non-diabetic 
control and male diabetic rats.  Similarly, Ohta et al. reported an elevated blood insulin level in 
spontaneously diabetic torii (SDT) female rats compared with SDT male rats (91).  In Ohta 
report, authors suggested that rising of blood glucose and declining of blood insulin level in male 
rats occurred earlier than in female rats.  In the current study, insulin sensitivity index (ISI) was 
lowered in diabetic groups, irrespective of sex.  However, when compared to male diabetic rats, 
female diabetic rats exhibited a lower ISI.  Accordingly, we showed that insulin signaling was 
impaired in the aortic tissues in diabetic groups in both sexes.  Particularly, aortic IRS-1 was 
reduced to a similar extent in both diabetic groups, but IRS-2 was reduced only in female 
diabetic group.  Along similar line, it has been reported that the downregulation of IRS-2 level in 
endothelial cell is induced by hyperinsulinemia in obese subjects (117).  Furthermore, in the 
current study, we showed that the ratio of p-Akt/Akt were significantly decreased in diabetic 
groups, regardless of sex, suggesting an impaired insulin signaling in these groups. 
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Endothelial dysfunction is considered to be an early step in the development of vascular 
complications in diabetes (17, 118, 119).  In T2D, impaired (104), enhanced (120) or preserved 
(105) EDV have been reported.  Similar with previous reports showing an impairment of EDV in 
aorta of T2D  (104, 121), we demonstrated that the maximal relaxation to ACh was significantly 
reduced in aortic rings from female UCD-T2DM rats compared to its respective controls.  
However, an intriguing observation of this study was that, aortic rings from male diabetic 
animals exhibited a potentiation in EDV compared with that in male control.  Similar 
observations were also made by our group using Zucker diabetic fatty (ZDF) male rats.  
Specifically, obesity-induced diabetes (ZDF model) significantly impaired relaxation responses 
to ACh in aortic rings taken from females, however, potentiated the relaxation in males (data not 
reported).  In accordance with our data, Zhong et al. reported an elevated relaxation responses to 
ACh in aortic rings of GK male rats (122). On the other hand, Nemoto et al. and Kazuyama et al. 
reported an impaired EDV in aortic rings from GK male rats. 
Sex-based differences in vascular function are well studied (123), and there are also 
several reports including ours on the effects of sex hormones on the vascular endothelial function 
in diabetic rabbits, rats and mice (51, 52, 100, 124, 125).   However, we are the first to 
characterize vascular function in the UCD-T2DM rat model with respect to sex.  It has been well 
established that in conduit arteries, NO plays the major role in EDV (42, 126).  The decreased 
ACh-induced relaxation observed in female diabetic arteries may in part result from decreased 
NO bioavailability or reduced in sensitivity of smooth muscle to NO in this group. 
It has been reported that T2D reduce the synthesis of NO in aorta by phosphorylation of 
eNOS at Ser1177 (127) and our results show that ratio of eNOS phosphorylation (peNOS) at this 
position over total eNOS is decreased in aortic tissues from both diabetic groups (although it 
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didn’t reach to significance level in female diabetic arteries) (Figure 13).  There is an established 
negative regulatory effect of NO on EDHF synthesis (128).   On the other hand, an augmented 
EDHF response was shown to compensate for the loss of NO-mediated vasorelaxation in arteries 
in diabetic rats (109, 129).  In agreement with those studies that demonstrate compensatory 
interactions between pathways, the potentiation of ACh response in aortic rings from male 
diabetic group suggests that other molecules besides NO (e.g., EDHF or PGI2) may be involved 
in ACh-relaxation in this group. 
Here, we showed that the inhibition of COX metabolites by Indo didn’t alter relaxation 
responses to ACh significantly in aortic rings of any of four experimental groups.  Consistent 
with these results, Malakul et al. reported hypercholesterolemia and type 1 diabetes did not have 
any effect on COX- mediated EDV in rat aorta (129). In the current study, addition of ODQ or L-
NNA completely abolished the EDV in aortic rings of both control groups and female diabetic 
group, but not in male diabetic rats.  The remaining of a slight but significant relaxation response 
to ACh after addition of L-NNA in male diabetic group, indicating a contribution of EDHF-type 
relaxation (in addition to NO) in this group (Figure 5B).  Along similar line, Malakul et al. 
reported a potential role of EDHF in EDV in aorta of type 1 diabetic male rat arteries (129).  
There are also reports of decreased NO-dependent relaxation response and increased EDHF 
activity in saphenous arteries (130) and carotid arteries (131) of high fat diet-induced obese male 
rats and STZ- induced type 1 diabetic male rats respectively. 
The reasons for the shift in the role of NO to both NO and EDHF in vasorelaxation of 
aorta in male diabetic group, but not in female diabetic rats is not clear.  However, this is 
consistent with our working hypothesis that the potentiated relaxation of aorta in this group may 
be partly attributed to the elevated response to EDHF.  
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Endothelial hyperpolarization-mediated by KCa channels has been suggested to play a 
critical role in initiating EDHF-type relaxation.  KCa currents are mainly mediated by IKCa and 
SKCa channels (132) on responses in conduit and resistance-sized arteries in many species, 
including humans (133, 134).  Next, we investigated whether inhibition of these channels 
influenced the EDV in the aortic rings from male diabetic group.  We demonstrated that 
inhibition of IKCa channels with TRAM-34 abolished EDV in male diabetic group to a greater 
extent than that in their non- diabetic controls (Table 4).   Accordingly, the protein expression 
level of both IKCa and SKCa channels were significantly greater in male diabetic group compared 
with the control rats (Figure 9).  These results are in accordance with Scach et al. who reported 
that T2D increased the expression and contribution of IKCa in mesenteric arteries of ZDF rats 
(135).  Regardless of higher SKCa channel expression, addition of Apamin had no effect on ACh-
mediated relaxation responses in the aortic rings from either male diabetic or male control rats 
(Figure 6).  Although IKCa and SKCa have the equal ability to generate KCa currents but it has 
been reported that these channels make distinct contributions to ACh-induced EDHF-mediated 
smooth muscle hyperpolarization (132).  Brahler et al. reported that IKCa plays a key role in 
ACh- induced smooth muscle hyperpolarization in mice carotid arteries (132).  Specifically, they 
showed that the loss of IKCa channels impaired the hyperpolarization of smooth muscle in a 
greater extent than the absence of SKCa channels (132).  In the current study, the overexpression 
of SKCa channels was not associated with a larger EDHF-mediated relaxation response in aorta 
of male diabetic group.  This maybe in line with Brahler et al. who reported that overexpression 
of SKCa channels in IKCa wild type mice did not produce a larger EDHF response (132).  It has 
been reported that the distinct role of these channels may be due to the spatial separation in the 
endothelium (132, 136).  SKCa channels are localized at endothelial cell junctions (132, 136, 137)  
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and possibly in caveolae (132, 138), and IKca channels are predominantly localized at 
endothelial projections through the holes in the elastic lamina  (132, 136, 137).  Therefore, those 
investigators concluded that IKCa channels can be activated by ACh-triggered Ca
2+ release events 
(132, 136, 137). 
Besides the possibility of altered contribution of EDRF, aortic dysfunction in UCD-
T2DM model may be explained by changes of smooth muscle responsiveness to NO or 
contractile agents.  We observed that SNP-induced relaxation of endothelium-denuded aortic 
rings was not altered male diabetic groups.  Similarly, Nemoto et al. also observed no significant 
difference in SNP-induced relaxation in aortic rings of male GK rats (127).  On the other hand, 
in the current study smooth muscle sensitivity NO was significantly reduced in female diabetic 
rats. These data suggest that decreased the vascular responsiveness to NO may in part be 
responsible for the impaired ACh-induced relaxation observed in aorta of diabetic female rats.   
In the current study, both sensitivity and maximum tension to PE were enhanced 
significantly in aortic rings of UCD-T2DM groups compared with their respective non- diabetic 
control, regardless of sex (Figure 11).  The elevated PE response may in part explain the 
decreased ACh-induced relaxation in aorta of female diabetic rats.  It is important to note that 
regardless of increased PE-induced contraction, ACh response potentiated in male diabetic 
arteries. This, therefore, excludes the diminished PE contractile responsiveness as the cause of 
the increased ACh responses observed in male diabetic arteries.  These data are in line with 
previous findings that type 1 diabetes results in increased vascular contraction in rat aorta (139) 
and mesenteric arteries (140).   
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The elevated contractile responses to PE observed in UCD-T2DM male and female rats 
may partially result from a decreased release of basal NO or an enhanced of contracting factors 
(52).  We assessed endothelium-derived NO by measuring the differences in the degree of PE-
induced contraction in the absence and presence of L-NAME (51, 141).  Pre-treatment with L-
NAME caused a significantly lower potentiation of the PE responses in aortic rings of UCD- 
T2DM rats, regardless of sex (Figure 12 B and D) compared with those in non- diabetic controls.  
This suggests that the decreased level of NO may in part be responsible for the elevated PE 
contractile responsiveness in UCD-T2DM rats. 
It has been reported that in diabetes, superoxide production may play a crucial role in 
enhancing the contracting responses (142-144).  The superoxide acts by scavenging NO, thus 
decreasing its bioavailability (145), will also elevate endothelium-dependent contractions.  In the 
present study, we did not directly measure NO or superoxide production.  However, we 
determined expression of Nox proteins in rat aorta.  Among the Nox isoforms, Nox1, Nox2 and 
Nox5 are considered as superoxide generating enzyme and promote endothelial dysfunction (25).  
On the other hand, Nox4 is hydrogen per oxide (H2O2) generating enzyme and has the 
vasoprotective effect (25-28).  Vascular walls express high levels of Nox1, Nox2 and Nox4 (29).  
Nox1 is mainly expressed in large conduit vessels (30), whereas Nox2 is more highly expressed 
in resistance vessels (31).  Here, we observed an elevated expression of Nox1 in aorta taken from 
diabetic groups, irrespective of sex, whereas Nox4 expression was not changed (Figure 14A and 
B).  Youn et al. reported that the activation of Nox1, but not Nox4 or Nox2, was associated with 
eNOS uncoupling and endothelial dysfunction in STZ-induced diabetic mice aorta (146).  Along 
the similar line Gray et al. reported genetic deletion of Nox1 in diabetic mice led to reduced 
diabetes mellitus symptoms suggesting a key role of Nox1 derived reactive oxygen species in 
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diabetes (147).  Therefore, our results on Nox1 overexpression in diabetic arteries suggest that 
the elevation of responses to PE observed in diabetic animals may be partially due to the elevated 
oxidative stress.  Further studies required to examine the level of superoxide which may be 
linked to sex-specific vascular function in UCD-T2DM rats. 
In conclusion, this study represents the first report showing that the aortic function in 
UCD-T2DM rats is altered in both sexes.  We also showed that basis for sex differences in the 
development of aortic dysfunction in this model may be partly attributed to changes in the 
importance of NO and EDHF to the regulation of vascular reactivity.  Specifically, potentiation 
of EDV in diabetic male arteries was associated to a shift from NO toward a reliance to both NO 
and EDHF.  Our data also suggest that a lower sensitivity to NO and/or enhanced responsiveness 
to contractile agents may contribute to the impaired EDV in aortic rings of UCD-T2DM female 
rats. 
 
 
 
 
 
 
 
82 
 
Chapter 3: Study II:  Effects of Estrogen Replacement in Aortic Function of Pre-diabetic 
Ovariectomized Rats 
3.1 Introduction 
Cardiovascular diseases (CVD) are the major causes of morbidity and mortality in 
patients with diabetes.  It is well established that hyperglycemia and diabetes affect male and 
female vascular beds differently (51, 52, 100, 148). Clinically, premenopausal women have a 
lower incidence of CVDs compared with age-matched men.  In premenopausal women the blood 
pressure and the prevalence of renal and heart diseases are much lower than age- matched men, 
but women loses this sex based protection with increasing age and decreasing level of estrogen 
after menopause (4-7, 149).   Several studies reported that women are less likely to meet low 
density lipoprotein cholesterol level and blood pressure goals compared to men with type 2 
diabetes and CVD (148, 150-152). This may be indicative of greater risk of CVD in association 
with diabetes in women than do men.  Therefore, women with diabetes not only lose their sex 
based cardiovascular protection but have a higher risk of morbidity and mortality compared to 
the age matched men (153, 154).   
It is well established that endothelial dysfunction represents early steps in the 
development of vascular complications in diabetes, and hyperglycemia is the central initiating 
factor for those complications.  Several reports have suggested that early, repeated episodes of 
asymptomatic hyperglycemia increase the risk of CVD even in absence of overt clinical 
symptoms of diabetes (155, 156).  Hyperglycemia can lead to several changes in vascular 
homeostasis, and endothelial dysfunction is one of the major hallmarks of hyperglycemia-
induced vascular disease which is characterized by reduced NO dependent vasodilation (157).   
Furthermore, premenopausal women with hyperglycemic condition, lose their gender-based 
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cardiovascular protection (156-158).   There is insufficient evidence to establish the timeline of 
the loss of female-specific protection in premenopausal patients with diabetes.  Thus, our 
objective of this study was to investigate the effects of 17β-estradiol (E2) replacement on aortic 
function in ovariectomized UC Davis type 2 diabetes mellitus (UCD-T2DM) rats at the 
prediabetic stage.  We also evaluated the expressions of specific proteins that are associated with 
aortic reactivity including eNOS, Nox1- and Nox4 dependent NADPH oxidase. 
3.2 Material and Methods 
3.2.1 Chemicals. All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), and dissolved in water, unless otherwise stated. 
3.2.2 Animals and experimental design. All animal protocols were approved by the 
Animal Care Committee of the University of the Pacific and complied with the Guide for the 
Care and Use of Laboratory Animals: Eighth Edition (2011).  Rats were euthanized using a 
carbon dioxide gas chamber according to the recommendations from the 2007 AVMA 
Guidelines on Euthanasia and the National Institutes of Health Guidelines for the Care and Use 
of Laboratory Animals.   
3.2.2.1 Rat model. UCD rats that their blood glucose level is high but not high enough to 
be considered diabetic are called pre-diabetic.  These animals have the potential to become 
diabetic at a later stage.  The Sprague-Dawley (SD) rats were used as non-diabetic/control, as 
these animals do not have the potential to become diabetic at any stages without manipulation. 
Ovariectomized female SD rats were purchased from Charles River (Wilmington, MA) 
and ovariectomized female pre-diabetic rats were purchased from University of California, 
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Davis.  All animals (ovariectomized SD and pre-diabetic rats) were implanted subcutaneously 
either with placebo or 17 β-estradiol pellets (60 days release, 1.5mg/pellets).  Rats were assigned 
to four different groups.  Group 1 was Control ovariectomized, placebo treated 
(Control+Placebo); group 2 was control ovariectomized, 17 β-estradiol (1.5mg/pellet)- treated 
(Control+E2); group 3 was pre-diabetic ovariectomized, placebo treated (Pre-diabetic+Placebo) 
and group 4 was pre-diabetic ovariectomized, 17 β-estradiol (1.5mg/pellet)- treated (Pre-diabetic 
+E2).  All animals were average 3.5-4 months old. 
3.2.3 Measurement of metabolic parameters in plasma. Blood glucose were measured 
in 12-h fasted rats using standard glucose test meter (OneTouch, LifeScan, CA) and triglycerides 
were measured by using an Accutrend Plus System (hand-held point-of-care device) and specific test 
strips (Roche Farma, Barcelona, Spain) with a drop of blood collected from the tail vein.  Blood 
samples were collected from intracardiac puncture and obtained in separate tubes containing heparin 
and sodium citrate as anticoagulants.  Plasma was obtained by centrifugation at 10,000xg for 5 min at 
4°C and stored at -80°C until used.  HbA1c was measured by using Bayer A1cNow test kit.  Blood 
sample was collected after sacrificing the animal to measure HbA1c.  The diluted sample was 
mixed and added to the monitor.  After adding the sample, the monitor begins the analyze and 
results will be displayed in the display window after 5 minutes. 
3.2.4 Measurement of arterial tension. The thoracic aortas were cut into 2mm rings 
after being excised and cleaned off adhering connective tissues.  To measure isometric tension, 
the rings were suspended horizontally between two stainless steel hooks in individual organ 
baths containing 20 ml of Krebs buffer (in mM: 119 NaCl, 4.7 KCl, 1.18 KH2PO4, 1.17 MgSO4, 
24.9 NaHCO3, 0.023 EDTA, 1.6 CaCl2, and 6.0 glucose) at 37°C bubbled with 95% O2 and 5% 
CO2.  Isometric tension was continuously monitored with a computer-based data acquisition 
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system (PowerLab; ADInstruments, Colorado Springs, CO).  To develop a stable basal tone, 
aortic rings were equilibrated under 1g resting tension for 40 min.  Rings were stimulated two 
times with 80mM KCl every 20 min until maximum contraction was achieved.  The ability of 
acetylcholine (ACh, 10 μM) to induce relaxation of phenylephrine (PE, 2 μM) pre-contracted 
vessels was taken as evidence for the preservation of an intact endothelium.  For the relaxation 
studies, we used an equal submaximal concentration of PE (2 μM) in all experimental groups. 
3.2.4.1 Relaxation responses to ACh. Aortic rings were precontracted with PE (2 µM), 
which represented a concentration that produced 80% of the maximal effect (EC80).  The 
concentration response curves (CRC) were obtained by the addition of increasing concentrations 
of ACh (10-8 to 10-5 M).   
3.2.4.2 Relaxation responses to Sodium Nitroprusside (SNP). Responses to SNP (10-9 to 
10-5 µM), a NO-donor, were obtained in the endothelium denuded aortic rings pre-contracted 
with PE (2 µM) taken from all experimental groups. 
3.2.4.3 Contractile responses to PE. The constrictor CRC to PE (10-8 to 10-5 M) were 
generated before and after incubation with Nω-Nitro-L-arginine methyl ester (L-NAME, 200 
μM), a NOS inhibitor in the presence of indomethacin (Indo, 10 μM, dissolved in DMSO), a 
COX inhibitor.  Between each CRC, tissues were washed with Krebs buffer to allow the rings to 
return to the basal tone.  A vehicle-only (no drugs present) study was performed simultaneously 
in aortic rings from the same animal (Data not shown). 
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3.2.4.4 Western blot analysis. 
3.2.4.4.1 Preparation of total protein extracts. Aortic tissue samples were micronized 
through freezing with liquid nitrogen and grinding with a mortar (111).  To obtain total protein 
extract, samples were incubated with RIPA buffer (Sigma-Aldrich, St. Louis, MO) containing 
Protease Inhibitor Cocktail (UltraCruz, Santa Cruz Biotechnology, Dallas, TX) for 1.5 h at 4°C 
and centrifuged at 1500xg for 15 min at 4°C, and supernatants were collected. Protein 
concentrations were by the bicinchoninic acid assay (BCA assay). 
Protein (20–30 µg) was subjected to SDS-polyacrylamide gel electrophoresis.  Proteins 
were then transferred to 0.45 µm Nitrocellulose Membranes (Bio Rad Laboratories Inc., 
Hercules, CA), blocked for 1 h at room temperature with 5% w/v BSA in 0.1% Tween 20-Tris-
buffered saline, and incubated overnight at 4°C with primary antibodies.  Primary antibodies 
forendothelial NO synthase (eNOS) were supplied by Cell Signaling (Boston, MA).  Antibodies 
against Nox1 and Nox4 were obtained from Abcam (Cambridge, MA).  Incubation with 
secondary antibody (LI-COR donkey anti-Rabbit IgG IRDye 680 or anti-mouse IgG IRDye 
800CW, 1: 10,000) was performed in the blocking buffer for 1 h at room temperature.  Before 
analyzing, the membrane was washed four times with TBS containing 0.1% Tween-20.  
Detection was done by using a LI-COR Odyssey imaging system (Lincoln, NE).  Uniformity of 
the protein loading was confirmed by incubating the blots with GAPDH and β- actin (Cell 
Signaling, Boston, MA) as a control. 
3.2.4.5 Measurement of plasma estradiol level. Plasma estradiol levels were assessed by 
using ELISA kit from Abcam (Cambridge, MA) according to manufacturer’s instruction. 
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3.2.4.6 Statistical analysis. All values were expressed as mean of n values ± standard 
error of the mean (SEM).  Here, n denotes data from one rat.  Relaxation responses to ACh- and 
SNP were calculated as the percentage of relaxation from maximum PE contraction at each 
concentration.  Similarly, the recorded increase in the force of contraction was calculated as the 
percentage of maximum contraction obtained with PE at the highest dose.  The concentration of 
the agonist, which produced half of the maximum effect (Emax) was expressed as EC50 and 
calculated by a sigmoidal dose-response model (for variable slope) using GraphPad Prism 7 
(GraphPad Software Inc., San Diego, CA).  The sensitivity of the agonists was expressed as pD2 
values (-log [EC50]), which were normally distributed.  The area under the curve (AUC) was 
determined using GraphPad Prism 7 with trapezoidal technique.  To compare the effect of 
pharmacological agents such as L-NAME on the PE response, the PE results were expressed as 
differences of area under the concentration-response curve (ΔAUC) in control (absence of drug) 
and experimental (presence of drug) condition.  Comparison of CRC between two groups was 
done using two-way ANOVA, with one factor being concentration and the other being groups 
(pre-diabetic vs control and placebo vs. E2).  When the ANOVA test returned P <0.05, post hoc 
analysis using Bonferroni’s or Tukey’s test was performed.  Comparison of CRC in a pre/post-
test format within a group was done using two-way ANOVA with repeated measures.  Student's 
unpaired t-test was used for comparisons of two group means.  A probability value of less than 
5% (P<0.05) was considered significant. 
3.3 Results 
3.3.1 Effects of 17β- estradiol (E2) replacement on plasma estradiol level. E2 
treatment significantly increased the concentrations of plasma E2 level in control and pre-diabetic 
rats compared to placebo treated animals (Figure 15).  In the current study plasma E2 
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concentrations were 4.46±1.10 pg/ml in placebo-treated control group, 45.24±17.05 pg/ml in E2-
treated control group, 1.60±0.58 pg/ml in placebo-treated pre-diabetic group and 49.27±12.54 
pg/ml in E2 treated pre-diabetic group. 
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Figure 15:  17β-estradiol (E2) level in plasma of placebo and E2 -treated control and pre-diabetic 
rats.  Data are expressed as mean±SEM. Capped lines indicate significant differences (P <0.05) 
between 2 groups, analyzed using Student’s unpaired t-test; n = 5 per group. 
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3.3.2 Effects of E2 replacement on metabolic parameters. E2 replacement significantly 
lowered the body weights of animals than those of placebo treated rats in both control and pre-
diabetic groups.  However, pre-diabetic animals had higher body weight compared to the control 
animals, regardless of treatment with E2.  (Table 8).  Accordingly, replacement with E2 lowered 
the adiposity in rats compared to the placebo treated groups of control and pre-diabetic rats.  
However, pre- diabetic animals had higher adiposity than control animals, irrespective of E2 
treatment.  Moreover, blood glucose and HbA1c levels were significantly reduced after treatment 
with E2 in both control and pre-diabetic rats.  
 
 
 
Table 8: Body weight and adipose weight, blood glucose levels and HbA1c of placebo and E2 
treated control and pre-diabetic rats 
 
  n Control+Placebo Control+E2 
Pre-
diabetic+Placebo 
Pre-diabetic+E2 
Body Weight 
(g) 
7-8 355.14±10.43# 224.24±7.78*^ 439.71±9.96 317.42±14.15* 
Adipose 
Tissue (g) 
6 15.61±2.13# 4.69±0.77*^ 27.75±1.72 7.73±0.48* 
Blood Glucose 
(mg/dl) 
6 153.83±6.18# 129.6±0.11* 182.33±12.87 131.5±8.30* 
HbA1c level 6 4.46±0.10# 4.00±0.00* 5.63±0.26 4.31±0.07* 
Data are expressed as mean ± SEM. *p<0.05 (vs. placebo treated, respective group), #p<0.05 
(vs. pre-diabetic+Placebo), ^p<0.05 (vs. pre-diabetic+E2), analyzed using Student’s unpaired t-
test 
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3.3.3 Effects of E2 replacement on relaxation responses to ACh. CRC to ACh were 
obtained to evaluate the effect of E2 and prediabetes on the receptor-mediated endothelium-
dependent release of NO.  ACh- induced relaxation responses were higher in placebo-treated 
controls than placebo-treated pre-diabetic group (Figure 17A).  In both control and pre-diabetic 
groups, treatment with E2 markedly enhanced the ACh-responses of aortic rings compared to 
respective placebo treated group (Figures 16A and 16B).  Both the Emax and sensitivity (as 
assessed by -log [EC50] (pD2)) to ACh were significantly enhanced in the aortic rings of E2 -
treated rats than those of placebo-treated animals regardless of being healthy or pre-diabetic 
(Table 9).  However, when compared to E2 -treated pre-diabetic animals, E2- treated controls 
expressed higher ACh- induced relaxation responses (Figure 17B). 
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Figure 16:  Relaxation response to cumulative concentrations of ACh (10-8 to 10-5 M) in intact 
aortic rings precontracted with phenylephrine (2 μM) from placebo and E2 treated control (A) or 
pre-diabetic (B) rats.  Data are expressed as means ±SEM. *P < 0.05 between two groups 
analyzed using 2-way ANOVA followed by Bonferroni’s post hoc test.  
 
 
 
 
 
Figure 17:  Relaxation response to ACh (10-8 to 10-5 M) in intact aortic rings precontracted with 
phenylephrine (2 μM) from placebo (A) and E2 (B) treated control and pre-diabetic rats.   
Data are expressed as means ± SEM. *P < 0.05 between two groups analyzed using 2-way 
ANOVA followed by Bonferroni’s post hoc test. 
Figure 17 is a different representation of same data shown in Figure 16. 
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Table 9:  pD2 and Emax to acetylcholine (ACh) in aortic rings from placebo and E2 treated control 
and pre-diabetic rats 
 
ACh n pD2 Emax % 
Control+ Placebo 5 6.70± 0.13 74.36±1.42 
Control+ E2 5 7.45±0.03* 96.69±1.66* 
Pre-diabetic+ Placebo 5 6.44±0.05 74.38±1.31 
Pre-diabetic+ E2 5 7.19±0.04*# 88.51±1.70*# 
Data are expressed as mean ± SEM; n, number of rats per group.  *p<0.05 (vs. placebo in 
respective group), #p<0.05 (vs. control+E2), analyzed using Student’s unpaired t-test.  
 
 
 
3.3.4 Effects of E2 replacement on relaxation responses to SNP. The smooth muscle 
sensitivity to NO was investigated by performing CRC to SNP (10-9 to 10-5 M) in endothelium -
denuded aortic rings.  In aortic rings from pre-diabetic groups, E2 treatment improved the 
sensitivity as assessed by pD2 values to SNP compared with placebo treated group (Figure 18B 
and Table 10).  However, no significant differences in CRC to SNP was observed in control 
groups, regardless of E2 treatment (Figure 18A and Table 10). 
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Figure 18:  Relaxation responses to cumulative concentrations of sodium nitroprusside (SNP, 10-
9 to 10-5 M) in endothelium denuded aortic rings pre-contracted with phenylephrine (PE, 2 μM) 
from placebo and E2 treated control (A) and pre-diabetic (B) rats.  Data are expressed as mean ± 
SEM. 
 
 
 
 
 
Figure 19: Relaxation responses to cumulative concentrations of sodium nitroprusside (SNP, 10-9 
to 10-5 M) in endothelium denuded aortic rings pre-contracted with phenylephrine (PE, 2 μM) 
from placebo (A) and E2 (B) treated control and pre-diabetic rats.  Data are expressed as mean ± 
SEM. 
Figure 19 is a different representation of same data shown in Figure 18. 
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Table 10:  pD2 and Emax to sodium nitroprusside (SNP) in rat aortic rings from placebo and E2 
treated control and pre-diabetic rats 
 
SNP n pD2 Emax, % 
Control+ Placebo 5 8.43± 0.17 100.11±0.38 
Control+ E2 5 8.45±0.12 101.31±0.66 
Pre-diabetic+ Placebo 5 8.15±0.18 100.98±0.34 
Pre-diabetic+ E2 5 8.76±0.08* 99.54±0.80 
 
 
Data are expressed as mean ± SEM; n, number of rats per group.  *P<0.05 (vs. placebo in respective 
group), analyzed using Student’s unpaired t-test. 
 
 
 
3.3.5 Effects of E2 replacement on contractile responses to PE. Contractile responses 
to α-adrenoceptors were analyzed by measuring the CRC to PE (10-8 to 10-5 M).  The tensionmax 
but not the sensitivity (as assessed by pD2) to PE were significantly decreased in E2 -treated pre-
diabetic and control groups compared with their respective placebo- treated groups (Figures 20A 
& 20B and Table 11).  
To indirectly measure the level of basal NO, CRC to PE (10-8 to 10-5 M) were performed 
in aortic rings before and after pretreatment with the NO synthase inhibitor, L-NAME (200 µM) 
in the presence of Indo (10 µM).  The changes in the contractile level to PE after addition of L-
NAME would reveal the effect of basal NO release on contraction (115, 116).  
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Incubation of the aortic rings with L-NAME resulted in a significant increase of the 
contractile responses to PE in all experimental groups (Figure 22).  However, as indicated by 
ΔAUC (the difference in area under the curve between PE CRC before and after L-NAME) were 
higher in aortas of E2 -treated pre-diabetic and control groups compared with their respective 
placebo-treated groups (Table 12).  However, when compared to pre-diabetic group, E2 -treated 
controls had a higher level of basal NO than E2-treated pre-diabetic rats as assessed by ΔAUC 
(Table12). 
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Figure 20:  Concentration-response curves to phenylephrine (PE, 10-8 to 10-5 M) in intact aortic 
rings of placebo and E2 -treated control (A) and pre-diabetic (B) rats.  Data are expressed as 
mean ± SEM. *P<0.05 between two groups analyzed using two-way ANOVA followed by 
Bonferroni’s post hoc test, n=5per group. 
 
  
 
 
 
 
Figure 21:  Concentration-response curves to phenylephrine (PE, 10-8 to 10-5 M) in intact aortic 
rings of placebo (A) and E2 (B) treated control and pre-diabetic rats.  Data are expressed as mean 
± SEM. 
Figure 21 is a different representation of same data shown in Figure 20. 
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Table 11:  pD2 and Tensionmax to phenylephrine (PE) in aortic rings from placebo and E2 treated 
control and pre-diabetic rats 
Data are expressed as mean ± SEM; n, number of rats per group.  *P<0.05 (vs. placebo in respective 
group), analyzed using Student’s unpaired t-test. 
 
 
 
 
 
 
 
 
 
PE n pD2 
Tension max 
(g) 
Control+ Placebo 5 7.04±0.03 1.99±0.17 
Control+ E2 5 6.98±0.06 1.43±0.08* 
Pre-diabetic+ Placebo 5 7.08±0.07 1.78±0.13 
Pre-diabetic+ E2 5 7.02±0.05 1.39±0.07* 
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Figure 22: Contractile response to cumulative concentrations of phenylephrine (PE, 10-8 to 10-5 
M) in intact aortic rings from control+ placebo (A), control+ E2 (B), pre-diabetic+ placebo (C) 
and pre-diabetic+ E2 (D) rats.  Contraction to PE was measured before and after incubation with 
Nω-Nitro-L-arginine methyl ester (L-NAME, 200 μM).  Responses were performed in the 
presence of indomethacin (10 μM).   Data are expressed as mean±SEM, with *P<0.05 vs. before 
L-NAME in all groups as analyzed using two-way ANOVA with repeated measures, n=5 per 
group. 
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Table 12:  ΔAUC, pD2 and Tensionmax to phenylephrine (PE) in aortic rings from placebo and E2 
treated control and pre-diabetic rats 
 
Data are expressed as mean± SEM. L-NAME, N-nitro-L-arginine methyl ester.  *P <0.05 vs. 
placebo in respective group (Same sex), #P<0.05 vs E2 treated control, Student’s Unpaired t-
Test; aP<0.05 vs before L- NAME, Student’s paired t-test.  n=5 per group. 
 
 
 
 
 
 
 
 
 
  Tensionmax, g pD2 ΔAUC 
Control+ Placebo 
Before L-NAME 1.69±0.60 6.97±0.07 
80.10±1.51 
After L-NAME 2.27±0.94a 7.16±0.08a 
Control+ E2 
Before L-NAME 1.56±0.21 7.02±0.05 
232.57±21.63* 
After L-NAME 2.26±0.19a 7.41±0.09a 
Pre-diabetic+ Placebo 
Before L-NAME 1.78±0.16 6.94±0.12 
85.68±2.81 
After L-NAME 2.30±0.13a 7.45±0.09a 
Pre-diabetic+ E2 
Before L-NAME 1.22±0.10 6.75±0.79 
139.58±10.49*# 
After L-NAME 2.19±0.07a 7.09±0.10a 
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3.3.6 Effects of E2 replacement on eNOS and Nox expression. To investigate the 
possible mechanisms underlying the elevated of the ACh responses in ovariectomized E2 -treated 
rats, the protein expression of eNOS and NADPH oxidase (Nox) subunits, Nox1 and Nox4 were 
measured.  Western blot analysis revealed that the expression of eNOS were significantly 
increased after treatment with E2 in control group (by 2.0 fold, Figure 23).  Although eNOS 
protein levels tended to be higher in E2 -treated pre-diabetic rats compared with placebo-treated 
pre-diabetic group, the difference did not reach to significance level  (Figure 23). 
The expressions of Nox1 was significantly reduced in aortic tissues taken from E2 -treated 
control and pre-diabetic groups (by 0.8 fold in control and by 0.5 fold in prediabetic, Figure 24). 
However, the protein expression of Nox4 showed no significant differences among all 
experimental groups (Figure 25). 
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Figure 23:  Western blots of eNOS normalized to GAPDH in aortic samples from placebo and E2 
-treated control and pre-diabetic rats.  Each bar represents the mean ± SEM of values obtained 
from n=5 animals.  To show representative bands images from different parts of the same gel 
have been juxtaposed, which is indicated by white dividing lines.  Capped lines indicate 
significant differences between two groups (P<0.05), as analyzed by Student’s unpaired t-test. 
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Figure 24: Western blots of Nox1 normalized to GAPDH in aortic samples from placebo and E2 -
treated control and pre-diabetic rats.  Values are represented as mean± SEM.  Each bar 
represents the values obtained from n=4-5 animals.  To show representative bands, images from 
different parts of the same gel have been juxtaposed, indicated by white dividing lines.  Capped 
lines indicate significant differences between two groups (P<0.05), as analyzed by Student’s 
unpaired t-test. 
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Figure 25:  Western blots of Nox4 normalized to GAPDH in aortic samples from placebo and E2 
-treated control and pre-diabetic rats.  Values are represented as mean± SEM.  Each bar 
represents the values obtained from n=4-5 animals.  To show representative bands, images from 
different parts of the same gel have been juxtaposed, indicated by white dividing lines.   
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3.4 Discussion 
This study is the first report on the effects of 17β-estradiol (E2) on aortic function in 
UCD-T2DM rats at the prediabetic stage.  Using pre-diabetic model enabled us to investigate the 
timeline of loss of endothelial function.  Furthermore, using ovariectomized animals with or 
without E2 replacement allowed us to examine the role of estrogen while investigating 
endothelial function at pre-diabetic stage.  The main findings of our investigation were that 1) the 
E2 replacement improved the endothelial function in both control and pre-diabetic 
ovariectomized groups but the impact was significantly higher in control group compared with 
the pre-diabetic animals,  and 2) E2 replacement elevated the basal NO level in both control and 
pre-diabetic group, but the effect of E2 was significantly higher in control group than that of pre-
diabetic group.  Accordingly, the protein expression level of eNOS were enhanced in both E2-
treated control group and pre-diabetic group but the effect was more prominent in control 
groups.  Furthermore, E2 treatment reduced the Nox1 level in control and pre-diabetic animals. 
In the current study, treatment with E2 increased the plasma estradiol levels in control and 
pre-diabetic rats.  Our data shows that, E2 replacement reduced the blood glucose level, HbA1c 
level, body weight and adipose tissue weight in control and pre-diabetic rats.  In accordance with 
previous studies decreased body weight (159-162), adiposity (159, 163), blood glucose level 
(160, 163) and HbA1c (164) have been reported with E2 -treated ovariectomized rats.   
Endothelium-dependent vasodilatation (EDV) is used as a reproducible parameter to 
probe endothelial function in different pathophysiological conditions.  Several lines of evidence 
suggest that the endothelial dysfunction represents early steps in the development of vascular 
complications in diabetes, and hyperglycemia is the central initiating factor for many types of 
vascular complications in diabetes (165-170).   It has been reported that E2 replacement improves 
106 
 
ACh- mediated relaxation responses in aortic rings of ovariectomized ZDF rats (160) and 
SD rats (160, 171, 172). Similar with previous reports, showing an improved EDV to 
ACh after E2 replacement in ovariectomized SD rat aorta (160, 171, 172), we 
demonstrated that treatment with E2 significantly enhanced the relaxation responses to 
ACh in control group compared to placebo treated controls.  However, the impact of E2 
in improving the relaxation response is significantly lower in pre-diabetic stage compared 
with the control animals. To our knowledge, no data has yet been published on the effect 
of E2 in ovariectomized pre-diabetic rats.  In the current study, we observed that maximal 
relaxation to ACh was significantly higher in aortic rings from ovariectomized UCD-
T2DM rats at pre-diabetic stage after E2 replacement compared with that in placebo- 
treated group.   
It has been well established that in conduit arteries, NO plays the major role in 
EDV (42, 126).  The lower ACh-induced relaxation observed in placebo treated control 
and pre-diabetic arteries may in part result from decreased NO bioavailability or reduced 
in sensitivity of smooth muscle to NO in this groups.  NO is produced in vascular 
endothelial cells by the enzyme endothelial nitric oxide synthase (eNOS) (173).  It has 
been reported that E2 enhanced eNOS expression in rat aorta (174, 175) and rat cerebral 
microvessels  (176).  Han et al. reported that E2 replacement improved endothelial 
dysfunction in aortic rings of ovariectomized ZDF rats by improving the eNOS 
expression and signaling network (160). Accordingly, we demonstrated that protein 
expression level of eNOS were higher in E2 treated groups compared with the placebo-
treated groups (although it didn’t reach to significance level in pre-diabetic group).  By 
contrast, Barbacanne et al. found no effect of E2 on eNOS expression in rat aorta (172).  
107 
 
The basis for discrepancy with Barbacanne et al. study, might be due to the difference in the 
duration of E2 administration.  
Besides the possibility of increased contribution of NO production, improved aortic 
endothelial function observed in E2 treated groups may be explained by changes of smooth 
muscle responsiveness to NO or contractile agents.  We observed that SNP-induced relaxation of 
endothelium-denuded aortic rings was not altered in control groups.  Similarly, Barbacanne et al. 
also observed no significant difference in SNP-induced relaxation in aortic rings of 
ovariectomized SD rats (127, 172).  On the other hand, in the current study smooth muscle 
sensitivity NO was significantly enhanced in pre-diabetic E2 -treated group.  These data suggest 
that increased vascular responsiveness to NO may in part be responsible for the improved ACh-
induced relaxation observed in aorta of this group.   
In the current study, maximum tension to PE were decreased significantly in aortic rings 
of E2 -treated groups compared with their respective placebo treated groups regardless of control 
and pre-diabetic condition.  The decreased PE response may in part explain the elevated ACh-
induced relaxation in aorta of E2 -treated rats.  These data are in line with Ping et al. who 
reported that E2 treatment attenuates the vascular contraction in hypertensive mice aorta (177).  
The attenuated contractile responses to PE observed in E2 -treated control and pre-
diabetic rats may partially result from the elevated release of basal NO or an enhanced of 
contracting factors (52, 178).  We assessed endothelium-derived NO indirectly by measuring the 
differences in the degree of PE-induced contraction in the absence and presence of L-NAME 
(51, 141).  It has been reported that treatment with E2 increases basal NO release in 
ovariectomized SD rat aorta (171). Here, we observed that pre-treatment with L-NAME caused a 
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significantly higher potentiation of the PE responses in aortic rings of E2 -treated rats not only in 
control but also in pre-diabetic group (Figure 20 B and D) compared with those in respective 
placebo treated rats.  This suggests that the increased level of NO may in part be responsible for 
the attenuated PE contractile responsiveness in E2 treated rats.  Moreover, when compared to E2- 
treated pre-diabetics, the basal NO level was significantly higher in E2 -treated controls.  
It has been reported that in diabetes and hyperglycemia, superoxide production may play 
a crucial role in enhancing the contracting responses (50, 142-144).  The superoxide acts by 
scavenging NO, thus decreasing its bioavailability (145) leading to endothelium-dependent 
contractions.  In the present study, we did not directly measure NO or superoxide production.  
However, we determined expression of Nox proteins in rat aorta.  Among the Nox isoforms, 
Nox1, Nox2 and Nox5 are considered as superoxide generating enzyme and promote endothelial 
dysfunction (25).  On the other hand, Nox4 is hydrogen per oxide (H2O2) generating enzyme and 
has the vasoprotective effect (25-28).  Vascular walls express high levels of Nox1, Nox2 and 
Nox4 (29).  In large conduit arteries, Nox1 is mainly expressed (30).  Here, we observed a 
decreased expression of Nox1 in aorta taken from E2 treated groups of control and pre-diabetic 
rats, whereas Nox4 expression was not changed (Figures 22 and 23).  It has been reported that E2 
treatment significantly reduced the Nox1 expression level in Wistar rat aorta (179).  Youn et al. 
reported that the activation of Nox1, but not Nox4 or Nox2, was associated with eNOS 
uncoupling and endothelial dysfunction in STZ-induced diabetic mice aorta (146).  Along the 
similar line Gray et al. reported genetic deletion of Nox1 in diabetic mice led to reduced diabetes 
mellitus symptoms suggesting a key role of Nox1 derived reactive oxygen species in diabetes 
(147).  Therefore, our results on attenuated expression of Nox1 in E2 -treated arteries of control 
and pre-diabetic groups suggest that the decreased contractile responses to PE or enhanced ACh-
109 
 
induced relaxation in E2 -treated control or pre-diabetic groups may be partially due to the 
reduced oxidative stress.  Further studies required to directly measure the level of superoxide and 
NO in the experimental groups. 
In conclusion, we showed that EDV was impaired in ovariectomized rats in both control 
and prediabetic groups.  E2 -replacement improved the endothelial function in both control and 
pre-diabetic groups possibly due to the elevated NO resulted from higher eNOS or lower Nox1 
expression in E2-treated groups. When compared to prediabetic groups, E2 -replacement had a 
higher impact on aortic function of control group.  This might be due to higher eNOS leading to 
higher basal NO in this group.  
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Chapter 4: Overall Conclusion 
 
We have shown that the aortic function are altered in UCD-T2DM rats and 
ovariectomized rats either in control or pre-diabetic groups.  Specifically, the important findings 
of study I are, aortic function is altered in a novel and validated model of type 2 diabetes (UCD-
T2DM rats) and sex differences exist in the development of abnormal vascular response. Our 
data shows that the lower sensitivity to NO and/or enhanced responsiveness to contractile agents 
contributed to the impaired EDV in aortic rings of UCD-T2DM female rats.  Particularly, 
potentiation of EDV in diabetic male arteries was associated to a shift from NO toward a reliance 
to both NO and EDHF.   In study II we showed that, E2 -replacement improved the endothelial 
function in both ovariectomized control and pre-diabetic groups.  The impact of E2 was 
significantly higher in control group which may be due to the higher NO resulted from lower 
Nox1 in this group.  
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Chapter 5: Limitation 
 
The effect of sex and diabetes on vascular activity varies in different vascular beds and 
species.  Clearly for investigation on specific diabetic macro-vascular complications, the use of 
coronary artery and cerebral artery is desired.  However, rat aorta was used in the current study. 
In addition, it is uncertain to what extent the rat model of diabetes can mimic human vascular 
disease in diabetes.  But, due to the relative difficulty in obtaining vascular samples from human, 
the rat models of diabetes are still widely used to unmask the mechanisms of diabetic vascular 
complications. 
Western blot analysis was done using whole aortic tissue, which contains both 
endothelial cells (ECs) and smooth muscle cells (SMCs).  Hence the increase or decrease in 
expression of proteins cannot be precisely attributed to ECs or SMCs. 
Here, we used UCD-T2DM rats.  Although this is model is validated model of type 2 
diabetes and it closely resembles the human T2DM, it is still under study and studies in certain 
areas such as hypertension remains to be determined. 
In study II, we used ovariectomized rats as preclinical model of menopause.  Although 
ovary secretes a multitude of hormones, only E2 was replaced in this study.  Therefore, the 
effects of progesterone and other ovarian hormones were not investigated.  Further studies 
required to examine the effects of sex hormones in ovariectomized UCD-T2DM rats in diabetic 
stage. 
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